var docs;if (!docs) docs =[]; docs["120"]={"12000":"<p><b>Title</b> Benzhydrocodone / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Benzhydrocodone. Specifically, the serum concentrations of hydrocodone may be reduced. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> In patients taking benzhydrocodone, monitor for decreased effects and withdrawal symptoms if a moderate CYP3A4 inducer is initiated. Conversely, monitor patients for increased hydrocodone toxicities, including fatal respiratory depression, if a moderate CYP3A4 inducer is discontinued. Consider benzhydrocodone dose adjustments until stable effects of the CYP3A4 inducer (either addition or removal) are achieved.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> The prescribing information for benzhydrocodone warns that because CYP3A4 plays a major role in hydrocodone metabolism, CYP3A4 inducers may increase the metabolism of hydrocodone (the active moiety of the prodrug benzhydrocodone) and lead to decreased plasma concentrations.<sup>1</sup> Lack of efficacy, or development of a withdrawal syndrome could occur. The prescribing information also contains a boxed warning detailing that discontinuation of any CYP3A4 inducer in benzhydrocodone-treated patients could result in an increase in hydrocodone plasma concentrations. This may prolong adverse drug effects and potentially lead to fatal respiratory depression. Monitor patients closely who are taking or discontinuing CYP3A4 inducers, and consider benzhydrocodone dose adjustments until stable drug effects are achieved.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Apadaz (benzhydrocodone and acetaminophen) [prescribing information]. Coralville, IA: KemPharm Inc; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12001":"<p><b>Title</b> Benzhydrocodone / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for increased benzhydrocodone toxicities, including fatal respiratory depression, if combined with a strong CYP3A4 inhibitor. Monitor patients at frequent intervals and consider benzhydrocodone dose reductions until stable drug effects are achieved.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the prescribing information, combination product ombitasvir, paritaprevir, ritonavir, and dasabuvir (a strong CYP3A4 inhibitor) increased the hydrocodone (5 mg single dose) AUC 1.9-fold in a study of 15 subjects.<sup>1</sup><br><br>The prescribing information for benzhydrocodone contains a boxed warning detailing that because CYP3A4 plays a major role in hydrocodone metabolism, concomitant use of benzhydrocodone and any CYP3A4 inhibitor could result in an increase in hydrocodone (the active moiety of the prodrug benzhydrocodone) plasma concentrations.<sup>2</sup> This increase in plasma concentrations may prolong adverse drug effects and potentially lead to fatal respiratory depression. If coadministration of a CYP3A4 inhibitor and benzhydrocodone is necessary, monitor patients for sedation and respiratory depression at frequent intervals and consider benzhydrocodone dose reductions until stable drug effects are achieved.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p>2. Apadaz (benzhydrocodone and acetaminophen) [prescribing information]. Coralville, IA: KemPharm Inc; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12002":"<p><b>Title</b> Benzhydrocodone / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for increased benzhydrocodone toxicities, including fatal respiratory depression, if combined with a moderate CYP3A4 inhibitor. Monitor patients at frequent intervals and consider benzhydrocodone dose reductions until stable drug effects are achieved.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the prescribing information, combination product ombitasvir, paritaprevir, ritonavir, and dasabuvir (a strong CYP3A4 inhibitor) increased the hydrocodone (5 mg single dose) AUC 1.9-fold in a study of 15 subjects.<sup>1</sup><br><br>The prescribing information for benzhydrocodone contains a boxed warning detailing that because CYP3A4 plays a major role in hydrocodone metabolism, concomitant use of benzhydrocodone and any CYP3A4 inhibitor could result in an increase in hydrocodone (the active moiety of the prodrug benzhydrocodone) plasma concentrations.<sup>2</sup> This increase in plasma concentrations may prolong adverse drug effects and potentially lead to fatal respiratory depression. If coadministration of a CYP3A4 inhibitor and benzhydrocodone is necessary, monitor patients for sedation and respiratory depression at frequent intervals and consider benzhydrocodone dose reductions until stable drug effects are achieved.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [prescribing information]. North Chicago, IL: AbbVie Inc.; June 2016.</p>\n<p>2. Apadaz (benzhydrocodone and acetaminophen) [prescribing information]. Coralville, IA: KemPharm Inc; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12003":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Benzhydrocodone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Benzhydrocodone may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The use of benzhydrocodone is not recommended for patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation. If benzhydrocodone is required during MAOI therapy, use test doses and frequent titration of small doses to treat pain while closely monitoring for signs of serotonin syndrome and opioid toxicity (eg, respiratory depression).</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The benzhydrocodone prescribing information states that concomitant use of monoamine oxidase inhibitors (MAOIs) and opioids may lead to serotonin syndrome or opioid toxicity (eg, respiratory depression, coma).<sup>1</sup> The use of benzhydrocodone is not recommended for patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Apadaz (benzhydrocodone and acetaminophen) [prescribing information]. Coralville, IA: KemPharm Inc; February 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12004":"<p><b>Title</b> Clopidogrel / CYP2C19 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2C19 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clopidogrel. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased clopidogrel effects and toxicities (eg, bleeding) if clopidogrel is combined with a strong CYP2C19 inducer.</p>\n<div>\n <p><b>CYP2C19 Inducers (Strong) Interacting Members</b> Apalutamide, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a study of 12 healthy volunteers, rifampin (300 mg twice daily for 14 days) coadministered with clopidogrel (600 mg loading dose followed by 75 mg daily for 7 days) increased the clopidogrel active metabolite AUC and maximum serum concentration approximately 4-fold.<sup>1</sup> The pharmacodynamic response to clopidogrel was also enhanced in the presence of rifampin.<sup>1</sup> In another study of 10 healthy volunteers, when rifampin (300 mg twice daily for 10 days) was coadministered with clopidogrel (75 mg daily for 6 days), clopidogrel-mediated inhibition of platelet aggregation was enhanced by rifampin (56% to 20% vs 33% to 18%; P = 0.001).<sup>2</sup> After rifampin, the 3 initial nonresponders and 1 low responder demonstrated enhanced platelet inhibition that then met the definition for a clopidogrel responder.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated, but rifampin-mediated induction of CYP2C19 (and possibly CYP3A4), enzymes responsible for the bioactivation of clopidogrel to its active metabolite, likely contributes. It is unclear if this enhancement of antiplatelet effects and increased active metabolite concentrations would lead to increased toxicities (eg, bleeding) or merely an enhancement of clopidogrel efficacy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Judge HM, Patil SB, Buckland RJ, Jakubowski JA, Storey RF. Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel. <i>J Thromb Haemost</i>. 2010;8(8):1820-1827. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20492465\">[PubMed 20492465]</a></p>\n<p>2. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. <i>Circulation</i>. 2004;109(2):166-171. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14707025\">[PubMed 14707025]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12005":"<p><b>Title</b> CNS Depressants / Bromopride</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bromopride may enhance the CNS depressant effect of CNS Depressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased sedation and CNS depression if bromopride is combined with other CNS depressants. Consider avoidance of this combination.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The bromopride product labeling states that the sedative effects of CNS depressants may be enhanced when combined with bromopride.<sup>1</sup> As such, monitor patients closely for sedation and CNS depression and consider avoiding concomitant use of CNS depressants during bromopride treatment.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Digesan (bromopride) [prescribing information]. Sao Paulo, Brazil: Sanofi-Aventis Farmaceutica Ltda; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12006":"<p><b>Title</b> Alcohol (Ethyl) / Bromopride</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bromopride may enhance the sedative effect of Alcohol (Ethyl). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid alcohol use during bromopride treatment.</p> \n<p><b>Discussion</b> The bromopride product labeling states that the sedative effects of alcohol may be enhanced when administered together with bromopride.<sup>1</sup> As such, patients should avoid consuming alcoholic beverages during treatment with bromopride.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Digesan (bromopride) [prescribing information]. Sao Paulo, Brazil: Sanofi-Aventis Farmaceutica Ltda; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12007":"<p><b>Title</b> Anti-Parkinson Agents (Dopamine Agonist) / Bromopride</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bromopride may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients with Parkinson disease that is being treated with a dopamine agonist should be monitored closely for worsening signs/symptoms (eg, rigidity, bradykinesia) following initiation of bromopride.</p>\n<div>\n <p><b>Anti-Parkinson Agents (Dopamine Agonist) Interacting Members</b> Amantadine, Apomorphine, Bromocriptine, Levodopa, Pergolide, Piribedil, Pramipexole, ROPINIRole, Rotigotine</p>\n</div> \n<p><b>Discussion</b> While no data describing this interaction is available with bromopride, this interaction has been reported with metoclopramide, a drug with a similar mechanism of action. A case report described 2 patients with diabetes and end-stage renal disease who developed extrapyramidal symptoms while receiving metoclopramide. One patient also had a history of Parkinson disease that had been well-controlled with levodopa prior to metoclopramide. After initiation of metoclopramide for gastroparesis, this patient experienced increased rigidity and bradykinesia that was refractory to levodopa and bromocriptine. In both patients, discontinuation of metoclopramide resulted in rapid resolution of all extrapyramidal symptoms.<sup>1</sup> A case-control study of patients 65 years of age or older showed that patients taking metoclopramide had three times greater odds of beginning levodopa than patients not taking metoclopramide [OR: 3.09 (95% CI: 2.25 to 4.26)], and this increase in odds was dose-dependent, with an OR=1.19 for metoclopramide doses = 10mg/day, OR=3.33 for doses of &gt;10-20mg/day, and OR=5.25 for doses of &gt;20mg/day.<sup>2</sup> The same study also investigated initiation of anticholinergic agents commonly used to treat Parkinson disease and, similarly, found evidence of increased initiation of such agents in metoclopramide users.<br><br>Conversely, other studies have reported that metoclopramide can be used so that it has little/no effect on response to dopamine agonists. A study in 10 subjects with parkinsonism found that pretreatment with a single 60mg dose of metoclopramide had no consistent effect on clinical response to bromocriptine (with separate single doses of 12.5mg, 25mg, 50mg, and 100mg).<sup>3</sup> Similarly, metoclopramide had no consistent effect on bromocriptine plasma concentrations or bromocriptine-induced increases in growth hormone concentrations. Metoclopramide has been shown in healthy volunteers to antagonize the reduced gastric emptying resulting from apomorphine administration,<sup>4</sup> and in healthy and hypertensive volunteers metoclopramide was shown to antagonize the blood pressure-lowering effects of bromocriptine, as well as the effects of bromocriptine on plasma aldosterone concentrations and plasma renin activity.<sup>5,6</sup> Others, however, have reported that metoclopramide does not antagonize the blood pressure effects of levodopa.<sup>7</sup><br><br>Some have attempted to take clinical advantage of the anti-dopaminergic effects of metoclopramide, investigating it as an antiemetic in patients receiving apomorphine. Parkinsonian patients receiving apomorphine 10mg and pretreated with metoclopramide (10mg) experienced diminished tremor and rigidity, and had reduced nausea, vomiting, and sleepiness.<sup>8</sup> In contrast, haloperidol (2mg) prevented both nausea/vomiting as well as the beneficial effects on tremor and rigidity associated with apomorphine administration. A letter describing experience with 40 patients with parkinsonism treated with levodopa and metoclopramide (30-80mg/d) reported that this combination resulted in reduced nausea and vomiting with no worsening of parkinsonism symptoms.<sup>9</sup> A double-blind study in 8 patients with parkinsonism by the same group also showed that 4 weeks of metoclopramide (30-60mg/d) had no effect on parkinsonism symptoms or levodopa-associated involuntary movements, unlike pimozide, another dopamine antagonist.<sup>10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sirota RA, Kimmel PL, Trichtinger MD, Diamond BF, Stein HD, Yudis M. Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases. <i>Arch Intern Med</i>. 1986;146(10):2070-2071. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3767555\">[PubMed 3767555]</a></p>\n<p>2. Avorn J, Gurwitz JH, Bohn RL, Mogun H, Monane M, Walker A. Increased incidence of levodopa therapy following metoclopramide use. <i>JAMA</i>. 1995;274(22):1780-1782. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7500509\">[PubMed 7500509]</a></p>\n<p>3. Price P, Debono A, Parkes JD, Marsden CD, Rosenthaler J. Plasma bromocriptine levels, clinical and growth hormone responses in parkinsonism. <i>Br J Clin Pharmacol</i>. 1978;6(4):303-309. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=359016\">[PubMed 359016]</a></p>\n<p>4. Ramsbottom N, Hunt JN. Studies on the effect of metoclopramide and apomorphine on gastric emptying and secretion in man. <i>Gut</i>. 1970;11(12):989-993. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5511820\">[PubMed 5511820]</a></p>\n<p>5. Luchsinger A, Grilli M, Velasco M. Metoclopramide and domperidone block the antihypertensive effect of bromocriptine in hypertensive patients. <i>Am J Ther</i>. 1998;5(2):81-88. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10099042\">[PubMed 10099042]</a></p>\n<p>6. Luchsinger A, Grilli M, Forte P, Morales E, Velasco M. Metoclopramide blocks bromocriptine induced antihypertensive effect in hypertensive patients. <i>Int J Clin Pharmacol Ther</i>. 1995;33(9):509-512. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8520809\">[PubMed 8520809]</a></p>\n<p>7. Parkes JD, Debono AG, Marsden CD. Bromocriptine in Parkinsonism: long-term treatment, dose-response, and comparison with levodopa. <i>J Neurol Neurosurg Psychiatry</i>. 1976;39(11):1101-1108. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1036999\">[PubMed 1036999]</a></p>\n<p>8. Corsini GU, Zompo MD, Cianchetti C, Mangoni A. Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in Parkinsonism. <i>Psychopharmacologia</i>. 1976;47(2):169-173. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1273213\">[PubMed 1273213]</a></p>\n<p>9. Tarsy D, Parkes JD, Marsden CD. Metoclopramide in Parkinsonism. <i>Lancet</i>. 1975;1(7918):1244-1245. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=48872\">[PubMed 48872]</a></p>\n<p>10. Tarsy D, Parkes JD, Marsden CD. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias. <i>J Neurol Neurosurg Psychiatry</i>. 1975;38(4):331-335. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1095689\">[PubMed 1095689]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12008":"<p><b>Title</b> Antipsychotic Agents / Bromopride</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bromopride may enhance the adverse/toxic effect of Antipsychotic Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of bromopride in combination with other agents associated with development of extrapyramidal reactions (eg, tardive dyskinesia) or neuroleptic malignant syndrome.</p>\n<div>\n <p><b>Antipsychotic Agents Interacting Members</b> Amisulpride, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Benperidol, Blonanserin, Brexpiprazole, Bromperidol, Cariprazine, ChlorproMAZINE, Clothiapine, CloZAPine, Droperidol, Flupentixol, FluPHENAZine, Haloperidol, Iloperidone, Loxapine, Lurasidone, Methotrimeprazine, Molindone, OLANZapine, Paliperidone, Periciazine, Perphenazine, Pimozide, Pipamperone [INT], Pipotiazine, Prochlorperazine, Promazine, QUEtiapine, RisperiDONE, Sulpiride, Thioridazine, Thiothixene, Trifluoperazine, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The bromopride product labeling states that the use of bromopride in combination with other agents associated with development of neuroleptic malignant syndrome or extrapyramidal reactions such as tardive dyskinesia should be avoided.<sup>1</sup><br><br>Dopaminergic activity within the nigrostriatal pathway (at dopamine D1 receptors) and striatopallidal pathway (at dopamine D2 receptors) regulates output from the basal ganglia which controls movement.<sup>2</sup> Metoclopramide inhibits central D2 receptors, which may cause an imbalance in dopaminergic activity between the nigrostriatal and striatopallidal pathways leading to movement-related side effects.<sup>3</sup> Other medications that inhibit central dopaminergic activity either directly (e.g. antipsychotics) or indirectly (e.g. serotonergic antidepressants) may increase the likelihood of serious movement-related side effects in patients receiving metoclopramide. The pathophysiology of neuroleptic malignant syndrome is poorly understood, but the syndrome is associated with many of the same drugs (e.g. antipsychotics, serotonergic antidepressants) as extrapyramidal side effects and similar precautions regarding the use of multiple associated agents should be taken.<sup>1,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Digesan (bromopride) [prescribing information]. Sao Paulo, Brazil: Sanofi-Aventis Farmaceutica Ltda; May 2016.</p>\n<p>2. Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. <i>Trends Neurosci</i>. 2000;23(Suppl):S64-S70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p>3. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. <i>Aliment Pharmacol Ther</i>. 2010;31(1):11-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19886950\">[PubMed 19886950]</a></p>\n<p>4. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18628446\">[PubMed 18628446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12009":"<p><b>Title</b> Deutetrabenazine / Bromopride</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bromopride may enhance the adverse/toxic effect of Deutetrabenazine. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of movement disorders such as parkinsonism or akathisia, as well as for neuroleptic malignant syndrome with concurrent use of deutetrabenazine and drugs with dopamine antagonist activities, such as bromopride.</p> \n<p><b>Discussion</b> The active deuterated dihydro metabolites of deutetrabenazine act as inhibitors of VMAT2 and work to deplete monoamine neurotransmitter stores in nerve terminals. According to deutetrabenazine labeling, akathisia, agitation, or restlessness was reported in 4% of deutetrabenazine users as compared to 2% in placebo-treated patients.<sup>1</sup> The labeling also contains warnings about parkinsonism and neuroleptic malignant syndrome, but it is unclear if such events have been reported with deutetrabenazine, though they have been associated with the closely related drug tetrabenazine.<br><br>Because many drugs with central dopamine antagonist actions have also been associated with movement disorders and neuroleptic malignant syndrome, the deutetrabenazine labeling states that use of such a combination may increase the risk for such effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Austedo (deutetrabenazine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12010":"<p><b>Title</b> Bromopride / Droperidol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Droperidol may enhance the adverse/toxic effect of Bromopride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of bromopride in combination with other agents associated with development of extrapyramidal reactions (eg, tardive dyskinesia) or neuroleptic malignant syndrome.</p> \n<p><b>Discussion</b> The bromopride product labeling states that the use of bromopride in combination with other agents associated with development of neuroleptic malignant syndrome or extrapyramidal reactions such as tardive dyskinesia should be avoided.<sup>1</sup><br><br>Dopaminergic activity within the nigrostriatal pathway (at dopamine D1 receptors) and striatopallidal pathway (at dopamine D2 receptors) regulates output from the basal ganglia which controls movement.<sup>2</sup> Metoclopramide inhibits central D2 receptors, which may cause an imbalance in dopaminergic activity between the nigrostriatal and striatopallidal pathways leading to movement-related side effects.<sup>3</sup> Other medications that inhibit central dopaminergic activity either directly (e.g. antipsychotics) or indirectly (e.g. serotonergic antidepressants) may increase the likelihood of serious movement-related side effects in patients receiving metoclopramide. The pathophysiology of neuroleptic malignant syndrome is poorly understood, but the syndrome is associated with many of the same drugs (e.g. antipsychotics, serotonergic antidepressants) as extrapyramidal side effects and similar precautions regarding the use of multiple associated agents should be taken.<sup>1,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Digesan (bromopride) [prescribing information]. Sao Paulo, Brazil: Sanofi-Aventis Farmaceutica Ltda; May 2016.</p>\n<p>2. Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. <i>Trends Neurosci</i>. 2000;23(Suppl):S64-S70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p>3. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. <i>Aliment Pharmacol Ther</i>. 2010;31(1):11-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19886950\">[PubMed 19886950]</a></p>\n<p>4. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18628446\">[PubMed 18628446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12011":"<p><b>Title</b> Bromopride / MetyroSINE</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> MetyroSINE may enhance the adverse/toxic effect of Bromopride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of bromopride in combination with other agents associated with development of extrapyramidal reactions (eg, tardive dyskinesia) or neuroleptic malignant syndrome.</p> \n<p><b>Discussion</b> The bromopride product labeling states that the use of bromopride in combination with other agents associated with development of neuroleptic malignant syndrome or extrapyramidal reactions such as tardive dyskinesia should be avoided.<sup>1</sup><br><br>Dopaminergic activity within the nigrostriatal pathway (at dopamine D1 receptors) and striatopallidal pathway (at dopamine D2 receptors) regulates output from the basal ganglia which controls movement.<sup>2</sup> Metoclopramide inhibits central D2 receptors, which may cause an imbalance in dopaminergic activity between the nigrostriatal and striatopallidal pathways leading to movement-related side effects.<sup>3</sup> Other medications that inhibit central dopaminergic activity either directly (e.g. antipsychotics) or indirectly (e.g. serotonergic antidepressants) may increase the likelihood of serious movement-related side effects in patients receiving metoclopramide. The pathophysiology of neuroleptic malignant syndrome is poorly understood, but the syndrome is associated with many of the same drugs (e.g. antipsychotics, serotonergic antidepressants) as extrapyramidal side effects and similar precautions regarding the use of multiple associated agents should be taken.<sup>1,4</sup> Metyrosine has been associated with development of extrapyramidal symptoms, likely as a result of its inhibitory effects on catecholamine synthesis.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Digesan (bromopride) [prescribing information]. Sao Paulo, Brazil: Sanofi-Aventis Farmaceutica Ltda; May 2016.</p>\n<p>2. Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. <i>Trends Neurosci</i>. 2000;23(Suppl):S64-S70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p>3. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. <i>Aliment Pharmacol Ther</i>. 2010;31(1):11-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19886950\">[PubMed 19886950]</a></p>\n<p>4. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18628446\">[PubMed 18628446]</a></p>\n<p>5. Prescribing information. Demser (metyrosine). Lawrenceville, NJ: Aton Pharma, Inc., February 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12012":"<p><b>Title</b> Promethazine / Bromopride</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bromopride may enhance the adverse/toxic effect of Promethazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of bromopride in combination with other agents associated with development of extrapyramidal reactions (eg, tardive dyskinesia) or neuroleptic malignant syndrome.</p> \n<p><b>Discussion</b> The bromopride product labeling states that the use of bromopride in combination with other agents associated with development of neuroleptic malignant syndrome or extrapyramidal reactions such as tardive dyskinesia should be avoided.<sup>1</sup><br><br>Dopaminergic activity within the nigrostriatal pathway (at dopamine D1 receptors) and striatopallidal pathway (at dopamine D2 receptors) regulates output from the basal ganglia which controls movement.<sup>2</sup> Metoclopramide inhibits central D2 receptors, which may cause an imbalance in dopaminergic activity between the nigrostriatal and striatopallidal pathways leading to movement-related side effects.<sup>3</sup> Other medications that inhibit central dopaminergic activity either directly (e.g. antipsychotics) or indirectly (e.g. serotonergic antidepressants) may increase the likelihood of serious movement-related side effects in patients receiving metoclopramide. The pathophysiology of neuroleptic malignant syndrome is poorly understood, but the syndrome is associated with many of the same drugs (e.g. antipsychotics, serotonergic antidepressants) as extrapyramidal side effects and similar precautions regarding the use of multiple associated agents should be taken.<sup>1,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Digesan (bromopride) [prescribing information]. Sao Paulo, Brazil: Sanofi-Aventis Farmaceutica Ltda; May 2016.</p>\n<p>2. Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. <i>Trends Neurosci</i>. 2000;23(Suppl):S64-S70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p>3. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. <i>Aliment Pharmacol Ther</i>. 2010;31(1):11-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19886950\">[PubMed 19886950]</a></p>\n<p>4. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18628446\">[PubMed 18628446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12013":"<p><b>Title</b> Quinagolide / Bromopride</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bromopride may diminish the therapeutic effect of Quinagolide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for signs/symptoms of inadequate quinagolide clinical response when used together with dopamine antagonists such as bromopride.</p> \n<p><b>Discussion</b> Specific data/studies regarding this potential interaction are not available. However, quinagolide works by acting as an agonist for the D2 receptor, meaning that drugs acting as dopamine antagonists (at the D2 receptor in particular) could, in theory, diminish the clinical response to quinagolide. Quinagolide product labeling states that a reduction of the therapeutic effect of quinagolide could be expected when drugs with strong dopamine antagonist properties are used concomitantly.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Norprolac (quinagolide) [product monograph]. Toronto, Ontario, Canada: Ferring Inc; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12014":"<p><b>Title</b> Bromopride / Rivastigmine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rivastigmine may enhance the adverse/toxic effect of Bromopride. Specifically, the risk of extrapyramidal adverse reactions may be increased with this combination. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of rivastigmine and bromopride because the risk of extrapyramidal adverse effects may be increased.</p> \n<p><b>Discussion</b> US prescribing information for rivastigmine recommends to avoid the combination of metoclopramide and rivastigmine due to the risk of additive extrapyramidal adverse reactions.<sup>1,2</sup><br><br>Cholinergic medications, such as rivastigmine, may exacerbate or induce extrapyramidal symptoms; worsening of parkinsonian symptoms was observed in patients with dementia<br>associated with Parkinson disease who were treated with rivastigmine.<sup>1,2</sup> Metoclopramide and bromopride may increase the risk of extrapyramidal adverse effects through their anti-dopaminergic action.<sup>3,4</sup> The combination may result in an additive risk of developing extrapyramidal adverse reactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Exelon (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015.</p>\n<p>2. Exelon Patch (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2015.</p>\n<p>3. Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2011.</p>\n<p>4. Digesan (bromopride) [prescribing information]. Sao Paulo, Brazil: Sanofi-Aventis Farmaceutica Ltda; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12015":"<p><b>Title</b> Selective Serotonin Reuptake Inhibitors / Bromopride</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bromopride may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of bromopride in combination with other agents associated with development of extrapyramidal reactions (eg, tardive dyskinesia) or neuroleptic malignant syndrome.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine, FluvoxaMINE, PARoxetine, Sertraline, Vilazodone, Vortioxetine</p>\n</div> \n<p><b>Discussion</b> The bromopride product labeling states that the use of bromopride in combination with other agents associated with development of neuroleptic malignant syndrome or extrapyramidal reactions such as tardive dyskinesia should be avoided.<sup>1</sup><br><br>Dopaminergic activity within the nigrostriatal pathway (at dopamine D1 receptors) and striatopallidal pathway (at dopamine D2 receptors) regulates output from the basal ganglia which controls movement.<sup>2</sup> Metoclopramide inhibits central D2 receptors, which may cause an imbalance in dopaminergic activity between the nigrostriatal and striatopallidal pathways leading to movement-related side effects.<sup>3</sup> Other medications that inhibit central dopaminergic activity either directly (e.g. antipsychotics) or indirectly (e.g. serotonergic antidepressants) may increase the likelihood of serious movement-related side effects in patients receiving metoclopramide. The pathophysiology of neuroleptic malignant syndrome is poorly understood, but the syndrome is associated with many of the same drugs (e.g. antipsychotics, serotonergic antidepressants) as extrapyramidal side effects and similar precautions regarding the use of multiple associated agents should be taken.<sup>1,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Digesan (bromopride) [prescribing information]. Sao Paulo, Brazil: Sanofi-Aventis Farmaceutica Ltda; May 2016.</p>\n<p>2. Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. <i>Trends Neurosci</i>. 2000;23(Suppl):S64-S70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p>3. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. <i>Aliment Pharmacol Ther</i>. 2010;31(1):11-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19886950\">[PubMed 19886950]</a></p>\n<p>4. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18628446\">[PubMed 18628446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12016":"<p><b>Title</b> Serotonin/Norepinephrine Reuptake Inhibitors / Bromopride</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bromopride may enhance the adverse/toxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of bromopride in combination with other agents associated with development of extrapyramidal reactions (eg, tardive dyskinesia) or neuroleptic malignant syndrome.</p>\n<div>\n <p><b>Serotonin/Norepinephrine Reuptake Inhibitors Interacting Members</b> Desvenlafaxine, DULoxetine, Levomilnacipran, Milnacipran, Venlafaxine</p>\n</div> \n<p><b>Discussion</b> The bromopride product labeling states that the use of bromopride in combination with other agents associated with development of neuroleptic malignant syndrome or extrapyramidal reactions such as tardive dyskinesia should be avoided.<sup>1</sup><br><br>Dopaminergic activity within the nigrostriatal pathway (at dopamine D1 receptors) and striatopallidal pathway (at dopamine D2 receptors) regulates output from the basal ganglia which controls movement.<sup>2</sup> Metoclopramide inhibits central D2 receptors, which may cause an imbalance in dopaminergic activity between the nigrostriatal and striatopallidal pathways leading to movement-related side effects.<sup>3</sup> Other medications that inhibit central dopaminergic activity either directly (e.g. antipsychotics) or indirectly (e.g. serotonergic antidepressants) may increase the likelihood of serious movement-related side effects in patients receiving metoclopramide. The pathophysiology of neuroleptic malignant syndrome is poorly understood, but the syndrome is associated with many of the same drugs (e.g. antipsychotics, serotonergic antidepressants) as extrapyramidal side effects and similar precautions regarding the use of multiple associated agents should be taken.<sup>1,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Digesan (bromopride) [prescribing information]. Sao Paulo, Brazil: Sanofi-Aventis Farmaceutica Ltda; May 2016.</p>\n<p>2. Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. <i>Trends Neurosci</i>. 2000;23(Suppl):S64-S70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p>3. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. <i>Aliment Pharmacol Ther</i>. 2010;31(1):11-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19886950\">[PubMed 19886950]</a></p>\n<p>4. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18628446\">[PubMed 18628446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12017":"<p><b>Title</b> Tetrabenazine / Bromopride</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bromopride may enhance the adverse/toxic effect of Tetrabenazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of bromopride in combination with other agents associated with development of extrapyramidal reactions (eg, tardive dyskinesia) or neuroleptic malignant syndrome.</p> \n<p><b>Discussion</b> The bromopride product labeling states that the use of bromopride in combination with other agents associated with development of neuroleptic malignant syndrome or extrapyramidal reactions such as tardive dyskinesia should be avoided.<sup>1</sup><br><br>Dopaminergic activity within the nigrostriatal pathway (at dopamine D1 receptors) and striatopallidal pathway (at dopamine D2 receptors) regulates output from the basal ganglia which controls movement.<sup>2</sup> Metoclopramide inhibits central D2 receptors, which may cause an imbalance in dopaminergic activity between the nigrostriatal and striatopallidal pathways leading to movement-related side effects.<sup>3</sup> Other medications that inhibit central dopaminergic activity either directly (e.g. antipsychotics) or indirectly (e.g. serotonergic antidepressants) may increase the likelihood of serious movement-related side effects in patients receiving metoclopramide. The pathophysiology of neuroleptic malignant syndrome is poorly understood, but the syndrome is associated with many of the same drugs (e.g. antipsychotics, serotonergic antidepressants) as extrapyramidal side effects and similar precautions regarding the use of multiple associated agents should be taken.<sup>1,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Digesan (bromopride) [prescribing information]. Sao Paulo, Brazil: Sanofi-Aventis Farmaceutica Ltda; May 2016.</p>\n<p>2. Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. <i>Trends Neurosci</i>. 2000;23(Suppl):S64-S70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p>3. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. <i>Aliment Pharmacol Ther</i>. 2010;31(1):11-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19886950\">[PubMed 19886950]</a></p>\n<p>4. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18628446\">[PubMed 18628446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12018":"<p><b>Title</b> Thiopental / Bromopride</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bromopride may enhance the therapeutic effect of Thiopental. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider thiopental dose reduction when used concomitantly with bromopride. Monitor patient response to treatment closely if using this combination.</p> \n<p><b>Discussion</b> No data are available that describe a potential interaction between thiopental and bromopride. Data to support this interaction comes from use of metoclopramide, a drug with a similar mechanism of action, and thiopental. Metoclopramide decreased thiopental requirements for induction of anesthesia (loss of ability to open eyes to verbal command) compared with saline placebo in a randomized, double-blind study composed of 2 series.<sup>1</sup> <br><br>In the first series, 28 unpremedicated subjects received continuous infusion thiopental (0.5 mg/kg/min) administered 5 minutes after intravenous metoclopramide (0.1, 0.2, or 0.4 mg/kg) or saline. The hypnotic end-point was tested every minute during drug administration and the total dose of thiopental required to reach the therapeutic end-point was determined. Thiopental dosage requirements were reduced 14%, 39%, and 45% in the metoclopramide 0.1, 0.2 and 0.4 mg/kg groups, respectively. A ceiling effect was demonstrated at the metoclopramide 0.4 mg/kg dose. <br><br>In the second series, 40 unpremedicated subjects received predetermined doses of thiopental (1 to 3 mg/kg) administered as one-time bolus injections 5 minutes after intravenous metoclopramide (0.2 mg/kg) or saline placebo. The hypnotic endpoint was determined 1 minute after the end of thiopental injection. Results showed that the ED50 value (effective dose for 50% of population) for thiopental decreased 44% in the subjects receiving metoclopramide.<sup>1</sup> <br><br>The product labeling for thiopental recommends lower doses of thiopental to induce anesthesia when metoclopramide is used concomitantly.<sup>2</sup> <br><br>Metoclopramide is a dopamine receptor antagonist. The mechanism of this possible interaction is dopamine receptor (D2) blockade, which may produce additive sedative effects to thiopental.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mehta D, Bradley EL Jr, Kissin I. Metoclopramide decreases thiopental hypnotic requirements. <i>Anesth Analg</i>. 1993;77(4):784-787. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8214666\">[PubMed 8214666]</a></p>\n<p>2. Thiopental sodium [Summary of Product Characteristics]. Berkshire, UK: Archimedes Pharma UK Limited; January 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12019":"<p><b>Title</b> Tricyclic Antidepressants / Bromopride</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bromopride may enhance the adverse/toxic effect of Tricyclic Antidepressants. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of bromopride in combination with other agents associated with development of extrapyramidal reactions (eg, tardive dyskinesia) or neuroleptic malignant syndrome.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> The bromopride product labeling states that the use of bromopride in combination with other agents associated with development of neuroleptic malignant syndrome or extrapyramidal reactions such as tardive dyskinesia should be avoided.<sup>1</sup><br><br>Dopaminergic activity within the nigrostriatal pathway (at dopamine D1 receptors) and striatopallidal pathway (at dopamine D2 receptors) regulates output from the basal ganglia which controls movement.<sup>2</sup> Metoclopramide inhibits central D2 receptors, which may cause an imbalance in dopaminergic activity between the nigrostriatal and striatopallidal pathways leading to movement-related side effects.<sup>3</sup> Other medications that inhibit central dopaminergic activity either directly (e.g. antipsychotics) or indirectly (e.g. serotonergic antidepressants) may increase the likelihood of serious movement-related side effects in patients receiving metoclopramide. The pathophysiology of neuroleptic malignant syndrome is poorly understood, but the syndrome is associated with many of the same drugs (e.g. antipsychotics, serotonergic antidepressants) as extrapyramidal side effects and similar precautions regarding the use of multiple associated agents should be taken.<sup>1,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Digesan (bromopride) [prescribing information]. Sao Paulo, Brazil: Sanofi-Aventis Farmaceutica Ltda; May 2016.</p>\n<p>2. Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. <i>Trends Neurosci</i>. 2000;23(Suppl):S64-S70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p>3. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. <i>Aliment Pharmacol Ther</i>. 2010;31(1):11-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19886950\">[PubMed 19886950]</a></p>\n<p>4. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18628446\">[PubMed 18628446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12020":"<p><b>Title</b> Trimetazidine / Bromopride</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bromopride may enhance the adverse/toxic effect of Trimetazidine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid use of bromopride in combination with other agents associated with development of extrapyramidal reactions (eg, tardive dyskinesia) or neuroleptic malignant syndrome.</p> \n<p><b>Discussion</b> The bromopride product labeling states that the use of bromopride in combination with other agents associated with development of neuroleptic malignant syndrome or extrapyramidal reactions such as tardive dyskinesia should be avoided.<sup>1</sup><br><br>Dopaminergic activity within the nigrostriatal pathway (at dopamine D1 receptors) and striatopallidal pathway (at dopamine D2 receptors) regulates output from the basal ganglia which controls movement.<sup>2</sup> Metoclopramide inhibits central D2 receptors, which may cause an imbalance in dopaminergic activity between the nigrostriatal and striatopallidal pathways leading to movement-related side effects.<sup>3</sup> Other medications that inhibit central dopaminergic activity either directly (e.g. antipsychotics) or indirectly (e.g. serotonergic antidepressants) may increase the likelihood of serious movement-related side effects in patients receiving metoclopramide. The pathophysiology of neuroleptic malignant syndrome is poorly understood, but the syndrome is associated with many of the same drugs (e.g. antipsychotics, serotonergic antidepressants) as extrapyramidal side effects and similar precautions regarding the use of multiple associated agents should be taken.<sup>1,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Digesan (bromopride) [prescribing information]. Sao Paulo, Brazil: Sanofi-Aventis Farmaceutica Ltda; May 2016.</p>\n<p>2. Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. <i>Trends Neurosci</i>. 2000;23(Suppl):S64-S70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p>3. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. <i>Aliment Pharmacol Ther</i>. 2010;31(1):11-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19886950\">[PubMed 19886950]</a></p>\n<p>4. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18628446\">[PubMed 18628446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12021":"<p><b>Title</b> Estrogen Derivatives / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Estrogen Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects and adverse effects of estrogens with concurrent use of any moderate CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n</div> \n<p><b>Discussion</b> The AUC of estrone (metabolite of estradiol) was significantly increased by an average of 16% to 27% when 17-beta-estradiol was coadministered with the moderate CYP3A4 inhibitor grapefruit juice in a study of 8 healthy women with bilateral ovariectomy.<sup>1</sup> While there was no significant effect on any AUC value for 17-beta-estradiol, the AUC of combined measured estrogens (17-beta-estradiol and estrone) increased by an average of 18% to 26%.<sup>2</sup> These relatively small increases in plasma concentrationswere not clearly associated with any adverse effects and are unlikely to be clinically relevant.<sup>2</sup> Similarly, the bioavailability of ethinyl estradiol (EE) increased by 30% with coadministration of grapefruit juice and EE in 13 healthy women.<sup>3</sup> Other studies observed a 29% and 24% increase in AUC of EE when coadministered with fluconazole 150 mg for one dose and 300 mg for 7 days, respectively.<sup>4,5</sup> The AUC of estradiol was also increased by an average of 30% when an oral contraceptive containing estradiol valerate and dienogest was administered with the moderate CYP3A4 inhibitor erythromycin (500 mg three times daily for 7 days) in a study of 24 healthy, postmenopausal women.<sup>6</sup> No safety concerns were noted, and the clinical relevance of these increases in estradiol exposure is uncertain.<sup>6</sup> These data are consistent with the prescribing information for various products containing estrogen derivatives that contain statements about the potential for CYP3A4 inhibitors to increase plasma concentrations of estrogens.<sup>1,7,8,9,10</sup><br><br>The likely mechanism of this interaction is inhibition of CYP3A4 metabolism of estrogen derivatives. Estrogens undergo significant first-pass metabolism, mostly via glucuronidation and sulfation, with the remaining via oxidation by CYP3A4.<sup>11</sup> Coadministration with moderate CYP3A4 inhibitors may potentially lead to decreased metabolism and increased plasma concentrations of estrogen, possibly increasing the risk for adverse effects such as vascular disease complications.<sup>11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Premarin (conjugated estrogens) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; December 2014.</p>\n<p>2. Schubert W, Cullberg G, Edgar B, Hedner T. Inhibition of 17 beta-estradiolmetabolism by grapefruit juice in ovariectomized women. <i>Maturitas</i>. 1994;20(2-3):155-163. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7715468\">[PubMed 7715468]</a></p>\n<p>3. Weber A, Jager R, Borner A, et al. Can grapefruit juice influence ethinylestradiol bioavailability? <i>Contraception</i>. 1996;53(1):41-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8631189\">[PubMed 8631189]</a></p>\n<p>4. Sinofsky FE, Pasquale SA. The effect of fluconazole on circulating ethinylestradiol levels in women taking oral contraceptives. <i>Am J Obstet Gynecol</i>. 1998;178(2):300-304. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9500490\">[PubMed 9500490]</a></p>\n<p>5. Hilbert J, Messig M, Kuye O, Friedman H. Evaluation of interaction between fluconazole and an oral contraceptive in healthy women. <i>Obstet Gynecol</i>. 2001;98(2):218-223. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11506836\">[PubMed 11506836]</a></p>\n<p>6. Blode H, Zeun S, Parke S, et al. Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women. <i>Contraception</i>. 2012;86(4):337-344. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22445438\">[PubMed 22445438]</a></p>\n<p>7. Estrace (estradiol) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Co.; March 2005.</p>\n<p>8. Ortho Tri-Cyclen (norgestimate/ethinyl estradiol) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; August 2017.</p>\n<p>9. Yaz (drospirenone/ethinyl estradiol) [prescribing information]. Whippany, NJ: Bayer HealthCare; August 2017.</p>\n<p>10. Natazia (estradiol valerate/dienogest) [prescribing information]. Whippany, NJ: Bayer HealthCare; August 2015.</p>\n<p>11. Zhang H, Cui D, Wang B, et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. <i>Clin Pharmacokinet</i>. 2007;46(2):133-157. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17253885\">[PubMed 17253885]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12022":"<p><b>Title</b> Estrogen Derivatives / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Estrogen Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects and adverse effects of estrogens with concurrent use of any strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n</div> \n<p><b>Discussion</b> The AUC of ethinylestradiol (EE) and estrone (metabolite of estradiol) were increased by an average of 1.4-fold with coadministration of an oral contraceptive containing drospirenone and EE or estradiol and the strong CYP3A4 inhibitor ketoconazole (200 mg twice daily for 10 days) in a study of 50 healthy, premenopausal women.<sup>1</sup> Because only a transient increase in EE concentrations were observed, this was deemed to be of unlikely clinical relevance and not likely to require a dose adjustment.<sup>1</sup> The AUC of estradiol was increased by an average of 1.6-fold when an oral contraceptive containing estradiol valerate and dienogest was administered with ketoconazole (400 mg/day) in a study of 24 healthy, postmenopausal women.<sup>2</sup> No safety concerns were noted, and the clinical relevance of the higher-than-intended systemic exposure to estradiol is unclear.<sup>2</sup> Similarly, the AUC of EE was increased by an average of 1.6-fold in a study of 16 healthy women who received the strong CYP3A4 inhibitor voriconazole (400 mg/day) with an oral contraceptive containing norethindrone and EE.<sup>3</sup> An increase in the AUC of voriconazole by 46% was also observed.<sup>3</sup> These data are consistent with the prescribing information for various products containing estrogen derivatives that contain statements about the potential for CYP3A4 inhibitors to increase plasma concentrations of estrogens.<sup>4,5,6,7,8</sup><br><br>The likely mechanism of this interaction is inhibition of CYP3A4 metabolism of estrogen derivatives. Estrogens undergo significant first-pass metabolism, mostly via glucuronidation and sulfation, with the remaining via oxidation by CYP3A4.<sup>9</sup> Coadministration with strong CYP3A4 inhibitors may potentially lead to decreased metabolism and increased plasma concentrations of estrogen, possibly increasing the risk for adverse effects such as vascular disease complications.<sup>9</sup><br><br>In contrast, a decrease in the AUC of EE up to 40% has been observed when protease inhibitors, such as ritonavir or boceprevir, where used concomitantly with EE.<sup>10,11</sup> The mechanism of this interaction is unclear but may be at least partially due to the potential for some protease inhibitors to induce the metabolism of estrogen derivatives.<sup>10</sup> With a decrease in plasma concentrations of estrogen, contraceptive failure is possible, and an alternative contraceptive method should also be used.<sup>10,11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Wiesinger H, Berse M, Klein S, et al. Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol. <i>Br J Clin Pharmacol</i>. 2015;80(6):1399-1410. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26271371\">[PubMed 26271371]</a></p>\n<p>2. Blode H, Zeun S, Parke S, et al. Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women. <i>Contraception</i>. 2012;86(4):337-344. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22445438\">[PubMed 22445438]</a></p>\n<p>3. Andrews E, Damle BD, Fang A, et al. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. <i>Br J Clin Pharmacol</i>. 2008;65(4):531-539. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18294327\">[PubMed 18294327]</a></p>\n<p>4. Premarin (conjugated estrogens) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; December 2014.</p>\n<p>5. Estrace (estradiol) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Co.; March 2005.</p>\n<p>6. Ortho Tri-Cyclen (norgestimate/ethinyl estradiol) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; August 2017.</p>\n<p>7. Yaz (drospirenone/ethinyl estradiol) [prescribing information]. Whippany, NJ: Bayer HealthCare; August 2017.</p>\n<p>8. Natazia (estradiol valerate/dienogest) [prescribing information]. Whippany, NJ: Bayer HealthCare; August 2015.</p>\n<p>9. Zhang H, Cui D, Wang B, et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. <i>Clin Pharmacokinet</i>. 2007;46(2):133-1357. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17253885\">[PubMed 17253885]</a></p>\n<p>10. Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. <i>Br J Clin Pharmacol</i>. 1998;46(2):111-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9723818\">[PubMed 9723818]</a></p>\n<p>11. Lin WH, Feng HP, Shadle CR, O'Reilly T, Wagner JA, Butterton JR. Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone. <i>Eur J Clin Pharmacol</i>. 2014;70(9):1107-1113. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24992979\">[PubMed 24992979]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12023":"<p><b>Title</b> Tacrolimus (Systemic) / Mycophenolate</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Mycophenolate may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> No action needed. Consider monitoring tacrolimus concentration levels more closely with use of this combination.</p> \n<p><b>Discussion</b> The tacrolimus AUC was increased by an average of 22% with coadministration of mycophenolate mofetil (MMF) in a study of 17 healthy Korean male volunteers who received MMF 1000 mg following a single dose of tacrolimus 5 mg for one week.<sup>1</sup> No changes in the pharmacokinetics of mycophenolic acid (MPA) or its metabolites were observed. A genotype dependent interaction was also described in which the apparent clearance of tacrolimus was further decreased in patients with CYP3A5 expression when MMF was coadministered with tacrolimus.<sup>1</sup> The tacrolimus AUC was increased by an average of 28% to 40%, although not statistically significant, with coadministration of MMF in a study of 18 stable post-renal transplant patients who received MMF at doses of 500 mg, 750 mg, or 1000 mg twice daily.<sup>2</sup> Similarly, an in vitro study observed a decrease in the metabolism of tacrolimus when exposed to MPA at concentrations above the plasma therapeutic range, causing the authors to suggest that tacrolimus may compete for CYP3A metabolizing enzymes with very high concentrations of MPA.<sup>3</sup> In contrast, no significant changes in the pharmacokinetic parameters of either tacrolimus or MMF were observed in a clinical study of 71 Japanese renal transplant patients who received both tacrolimus and MMF.<sup>4</sup><br><br>The proposed mechanism of the interaction is unclear. One in vitro study suggests that MPA may also undergo oxidation via CYP3A and competitively inhibit tacrolimus CYP3A metabolism.<sup>2</sup> Since this interaction has been reported with varying MMF doses, and since there is a lack of clinical data showing MMF is a CYP3A inhibitor, this seems an unlikely mechanism.<br><br>Other studies have observed increased plasma concentrations of MPA when MMF is coadministered with tacrolimus compared to cyclosporine.<sup>5,6,7,8</sup> However, these studies only compared patients treated with MMF and tacrolimus to patients treated with MMF and cyclosporine; therefore, it is unclear if the difference in MPA plasma concentrations was as a result of an increase with tacrolimus or a decrease with cyclosporine.<sup>7,9</sup> It has been well-established that cyclosporine interacts with MMF by inhibiting the multidrug-resistance-associated protein 2 (MRP-2) transporter and preventing enterohepatic recirculation of MPA.<sup>10</sup> In a study summarized in the Cellcept prescribing information, administration of MMF alone results in a 30-50% increase in plasma concentrations of MPA compared to when coadministered with cyclosporine.<sup>10</sup> The Prograf prescribing information further cautions that exposure to MPA is increased with tacrolimus coadministration compared to cyclosporine coadministration because tacrolimus does not inhibit enterohepatic recirculation like cyclosporine.<sup>11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kim JH, Han N, Kim MG, et al. Increased exposure of tacrolimus by co-administered mycophenolate mofetil: population pharmacokinetic analysis in healthy volunteers. <i>Sci Rep</i>. 2018;8(1):1687. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29374217\">[PubMed 29374217]</a></p>\n<p>2. Pirsch J, Bekersky I, Vincenti F, et al. Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. <i>J Clin Pharmacol</i>. 2000;40(5):527-532. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10806606\">[PubMed 10806606]</a></p>\n<p>3. Picard N, Cresteil T, Premaud A, Marquet P. Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. <i>Ther Drug Monit</i>. 2004;26(6):600-608. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15570183\">[PubMed 15570183]</a></p>\n<p>4. Kagaya H, Miura M, Satoh S, et al. No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. <i>J Clin Pharm Ther</i>. 2008;33(2):193-201. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18315786\">[PubMed 18315786]</a></p>\n<p>5. Prograf (tacrolimus) [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc.; February 2015.</p>\n<p>6. CellCept (mycophenolate mofetil) [prescribing information]. Nutley, NJ: Roche Laboratories Inc.; July 2015.</p>\n<p>7. Hubner GI, Eismann R, Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. <i>Ther Drug Monit</i>. 1999;21(5):536-539. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10519451\">[PubMed 10519451]</a></p>\n<p>8. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. <i>Transpl Immunol</i>. 1997;5(3):225-232. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9402690\">[PubMed 9402690]</a></p>\n<p>9. Zucker K, Rosen A, Tsaroucha A, et al. Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy. <i>Transplant Proc</i>. 1997;29(1-2):334-336. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9123027\">[PubMed 9123027]</a></p>\n<p>10. Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, Miller J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. <i>Ther Drug Monit</i>. 1999;21(1):35-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10051052\">[PubMed 10051052]</a></p>\n<p>11. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. <i>Ther Drug Monit</i>. 2001;23(2):119-128. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11294511\">[PubMed 11294511]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12024":"<p><b>Title</b> Erlotinib / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amiodarone may increase the serum concentration of Erlotinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of erlotinib-related adverse effects, including neurotoxicity.</p> \n<p><b>Discussion</b> A case report describes a male with NSCLC being treated with erlotinib 150 mg daily who began to experience signs of lightheadedness, weakness, paresthesia, and loss of muscle strength approximately five hours after a loading dose of amiodarone 300 mg given intravenously to manage new-onset atrial fibrillation.<sup>1</sup> The patient continued in atrial fibrillation and thus received additional doses of amiodarone. An extensive neurologic workup was conducted to rule out other causes for these symptoms, and the patient was ultimately placed on enoxaparin out of suspicion for a transient ischemic attack secondary to the atrial fibrillation. Four days later, the patient presented with hemiparesis and generalized tonic-clonic seizures and was started on clonazepam. Several days later the patient was discharged on erlotinib and amiodarone, but returned that same day after recurring signs of intermittent paralysis in lowering extremities. The authors concluded that the patient's symptoms could have been due to an interaction between erlotinib and amiodarone.<br><br>Amiodarone is not specifically listed as a potential interacting medication in the prescribing information for erlotinib.<sup>2</sup> The potential mechanism of this interaction is unclear, but may be due to the amiodarone-mediated inhibition of p-glycoprotein (p-gp) leading to increased concentrations of erlotinib. P-gp does appear capable of transporting erlotinib, but the clinical significance of p-gp-mediated efflux in determining erlotinib disposition is unclear. The erlotinib product summary published by the European Medicines Agency mentions that use of erlotinib with p-gp inhibitors may lead to an alteration in distribution and elimination,<sup>3</sup> although the outcome of this interaction has not been well established. Altered erlotinib distribution may also help to explain, at least in part, the observed neurotoxicity in this case. This atypical presentation of erlotinib toxicity (primarily gastrointestinal mediated through CYP3A4 inhibition) may have been the result of increased central nervous system availability due to impaired p-gp efflux at the blood-brain barrier, leading to the observed neurological presentation. An influence of CYP3A4 inhibition cannot be exclusively rejected, but amiodarone is only a weak CYP3A4 inhibitor, suggesting this is unlikely to be the primary mechanism for this potential interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lopez Brunso M, Toro Blanch C, Sais Girona E, et al. Probable drug-drug interaction between erlotinib and amiodarone causes severe neurotoxicity in a patient with advanced lung cancer. <i>Anticancer Drugs</i>. 2018; Feb 7 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29420339\">[PubMed 29420339]</a></p>\n<p>2. Tarceva (erlotinib) [prescribing information]. Northbrook, IL: OSI Pharmaceuticals, LLC; April 2014.</p>\n<p>3. Tarceva (erlotinib) [summary of product characteristics]. Welwyn Garden City, United Kingdon: Roche Registration Limited; 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12025":"<p><b>Title</b> Sonidegib / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of Sonidegib. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> The AUC of sonidegib was reduced by 32% to 38% when combined with esomeprazole compared to sonidegib alone in a phase 1 pharmacokinetic study of participants who received either a single dose of sonidegib 200 mg alone or sonidegib 200 mg in combination with esomeprazole 40 mg.<sup>1</sup><br><br>According to the prescribing information, concurrent use of acid-lowering therapy with sonidegib is not considered a clinically significant interaction.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zhou J, Quinlan M, Glenn K, et al. Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers. <i>Br J Clin Pharmacol</i>. 2016;82(4):1022-1029. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27277189\">[PubMed 27277189]</a></p>\n<p>2. Odomzo (sonidegib) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12031":"<p><b>Title</b> Amodiaquine / CYP2C8 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP2C8 Inhibitors (Strong) may increase the serum concentration of Amodiaquine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Coadministration of amodiaquine with CYP2C8 inhibitors is not recommended in the absence of clinical data supporting such combined use.</p>\n<div>\n <p><b>CYP2C8 Inhibitors (Strong) Interacting Members</b> Gemfibrozil</p>\n</div> \n<p><b>Discussion</b> Labeling for the artesunate/amodiaquine product cautions that, in the absence of clinical data, coadministration with CYP2C8 inhibitors is not recommended.<sup>1</sup> Specific data concerning this interaction are not available.<br><br>Amodiaquine is a substrate for CYP2C8, suggesting that concurrent use with an inhibitor of CYP2C8 may lead to impaired amodiaquine metabolism, increased serum concentrations, and an increased risk for toxicities and adverse effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Artesunate Amodiaquine Winthrop (artesunate, amodiaquine) [summary of product characteristics]. Gentilly, France: Sanofi-aventis; August 2010. (http:// www.wipo.int/export/sites/www/research/en/data/sanofi/marketed_ products/Artesunate_and_Amodiquine.pdf)</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12032":"<p><b>Title</b> Amodiaquine / CYP2C8 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Amodiaquine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Coadministration of amodiaquine with CYP2C8 inhibitors is not recommended in the absence of clinical data supporting such combined use.</p>\n<div>\n <p><b>CYP2C8 Inhibitors (Moderate) Interacting Members</b> Clopidogrel, Deferasirox, Leflunomide, Teriflunomide</p>\n</div> \n<p><b>Discussion</b> Labeling for the artesunate/amodiaquine product cautions that, in the absence of clinical data, coadministration with CYP2C8 inhibitors is not recommended.<sup>1</sup> Specific data concerning this interaction are not available.<br><br>Amodiaquine is a substrate for CYP2C8, suggesting that concurrent use with an inhibitor of CYP2C8 may lead to impaired amodiaquine metabolism, increased serum concentrations, and an increased risk for toxicities and adverse effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Artesunate Amodiaquine Winthrop (artesunate, amodiaquine) [summary of product characteristics]. Gentilly, France: Sanofi-aventis; August 2010. (http:// www.wipo.int/export/sites/www/research/en/data/sanofi/marketed_ products/Artesunate_and_Amodiquine.pdf)</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12033":"<p><b>Title</b> Clorazepate / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antacids may decrease serum concentrations of the active metabolite(s) of Clorazepate. Specifically, concentrations of desmethyldiazepam may be decreased. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> Impaired absorption of clorazepate, in association with antacid administration, has been reported.<sup>1</sup> In a study conducted in 10 healthy volunteers, the maximum serum concentration and AUC of desmethyldiazepam (the active moiety of clorazepate responsible for clinical activity) decreased 31% and 10%, respectively, following ingestion of clorazepate (single 15 mg dose) with magnesium aluminum hydroxide (60 mL).<sup>1</sup><br><br>In contrast, a study that evaluated healthy subjects on long-term clorazepate therapy (7.5 mg nightly for 30 consecutive nights) found that antacid regimens did not influence steady-state plasma desmethyldiazepam concentrations.<sup>2</sup> In another study conducted in 15 healthy adults, the AUC of desmethyldiazepam was not affected by antacid treatments.<sup>3</sup><br><br>The chlorazepate prescribing information states that coadministration of antacids at therapeutic levels did not significantly influence the bioavailability of clorazepate tablets in studies with normal subjects.<sup>4</sup><br><br>The mechanism of this potential interaction may be due to decreased conversion of clorazepate to desmethyldiazepam, which requires an acidic environment.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Shader RI, Georgotas A, Greenblatt DJ, Harmatz JS, Allen MD. Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. <i>Clin Pharmacol Ther</i>. 1978;24(3):308-315. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28870\">[PubMed 28870]</a></p>\n<p>2. Shader RI, Ciraulo DA, Greenblatt DJ, Harmatz JS. Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids. <i>Clin Pharmacol Ther</i>. 1982;31(2):180-183. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6120059\">[PubMed 6120059]</a></p>\n<p>3. Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD. Effect of antacids on absorption of clorazepate. <i>Clin Pharmacol Ther</i>. 1977;22(3):329-335. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19188\">[PubMed 19188]</a> </p>\n<p>4. Tranxene (clorazepate dipotassium) [prescribing information]. Barceloneta, PR: AbbVie LTD; September 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12034":"<p><b>Title</b> ChlordiazePOXIDE / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of ChlordiazePOXIDE. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> Delayed absorption of chlordiazepoxide, in association with antacid administration, has been reported.<sup>1</sup> In a study of 10 healthy male subjects who ingested a single dose of chlordiazepoxide (25 mg), the time to peak blood concentration increased by 500% following ingestion with magnesium and aluminum hydroxide (100 mL).<sup>1</sup> The AUC for chlordiazepoxide and its metabolite were not influenced by the antacid.<sup>1</sup><br><br>The mechanism of this presumed interaction is unclear. The delay in absorption could be due to reversible adsorption of the drug by its components or delayed gastric emptying by the antacid.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J. Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption. <i>Clin Pharmacol Ther</i>. 1976;19(2):234-239. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=770046\">[PubMed 770046]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12035":"<p><b>Title</b> DiazePAM / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of DiazePAM. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> Reduced absorption rate of diazepam, in association with antacid administration, has been reported.<sup>1</sup> In a study conducted in 9 healthy fasting volunteers who received a single dose of oral diazepam (5 mg), the maximum serum concentration (Cmax) of diazepam decreased 28% following administration with aluminum hydroxide trisilicate mixture (60 mL) and 34% following administration with magnesium aluminum hydroxide mixture (60 mL).<sup>1</sup> The AUC of diazepam was not influenced.<br><br>In contrast, in a study of 11 healthy fasting subjects who received a single oral dose of slow-release diazepam (15 mg) with a magnesium and aluminum hydroxide mixture (60 mL), the diazepam Cmax and AUC increased 30% and 12%, respectively.<sup>2</sup> Another study found the absorption of diazepam increased with concomitant use of aluminum hydroxide but not with magnesium trisilicate or sodium citrate.<sup>3</sup><br><br>The diazepam prescribing information states diazepam peak concentrations are 30% lower when antacids are administered concurrently, but there is no effect on the extent of absorption. The lower peak concentrations appear due to a slower rate of absorption, with the time required to achieve peak concentrations on average 20 to 25 minutes greater in the presence of antacids. However, this difference was not statistically significant.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI. Diazepam absorption: effect of antacids and food. <i>Clin Pharmacol Ther</i>. 1978;24(5):600-609. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=699484\">[PubMed 699484]</a></p>\n<p>2. Nair SG, Gamble JA, Dundee JW, Howard PJ. The influence of three antacids on the absorption and clinical action of oral diazepam. <i>Br J Anaesth</i>. 1976;48(12):1175-1180. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1023953\">[PubMed 1023953]</a></p>\n<p>3. Locniskar A, Greenblatt DJ, Zinny MA, Harmatz JS, Shader RI. Absolute bioavailability and effect of food and antacid on diazepam absorption from a slow-release preparation. <i>J Clin Pharmacol</i>. 1984;24(5-6):255-263. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6747022\">[PubMed 6747022]</a></p>\n<p>4. Valium (diazepam) [prescribing information]. South San Francisco, CA: Hoffman-La Roche; December 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12036":"<p><b>Title</b> Triazolam / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antacids may increase the serum concentration of Triazolam. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> Enhanced absorption of triazolam, in association with antacid administration, has been reported in dialysis patients.<sup>1</sup> In a study of 11 dialysis patients who took triazolam (0.5 mg single dose), the maximum serum concentration and AUC increased 59% and 28%, respectively, following ingestion with aluminum hydroxide suspension (3,600 mg).<sup>1</sup> <br><br>The mechanism of this interaction is unknown and it is unclear if this same increase in triazolam concentrations would occur in patients with normal renal function.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kroboth PD, Smith RB, Silver MR, et al. Effects of end stage renal disease and aluminum hydroxide on triazolam pharmacokinetics. <i>Br J Clin Pharmacol</i>. 1985;19(6):839-842. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2862896\">[PubMed 2862896]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12037":"<p><b>Title</b> BusPIRone / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of BusPIRone. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The significance of the effect of strong CYP3A4 inducers on buspirone exposure warrants the consideration of alterative therapy. If coadministration of these agents is deemed necessary, monitor patients for reduced buspirone effects and increase buspirone doses as needed. Buspirone doses will likely need to be reduced when a strong CYP3A4 inducer is discontinued.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The AUC of a single dose of buspirone (30 mg) was decreased by more than 90% in 10 healthy volunteers when administered following a 5-day course of rifampin (600 mg daily), a strong CYP3A4 inducer.<sup>1</sup> Buspirone half-life was approximately halved, and psychomotor effects were diminished.<sup>1</sup> Similarly, the mean buspirone AUC and maximum serum concentration were reduced 91% and 85%, respectively, when buspirone (30 mg single dose) was given after 5 days of rifampin (600 mg daily) in a study of 6 healthy volunteers.<sup>2</sup><br><br>The buspirone prescribing information states that if potent CYP3A4 inducers and buspirone are to be used in combination, the dosage of buspirone may need adjusting to maintain anxiolytic effects.<sup>3</sup><br><br>The mechanism of this interaction is due to induction of CYP3A4, an enzyme responsible for buspirone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lamberg TS, Kivisto KT, Neuvonen PJ. Concentrations and effects of buspirone are considerably reduced by rifampin. <i>Br J Clin Pharmacol</i>. 1998;45(4):381-385. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9578186\">[PubMed 9578186]</a></p>\n<p>2. Kivisto KT, Lamberg TS, Neuvonen PJ. Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone. <i>Pharmacol Toxicol</i>. 1999;84(2):94-97. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10068153\">[PubMed 10068153]</a></p>\n<p>3. Buspar (buspirone hydrochloride) [prescribing information]. Princeton, NJ. Bristol-Myers Squibb Company; November 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12038":"<p><b>Title</b> Tamoxifen / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Strong) may decrease the serum concentration of Tamoxifen. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to concomitant use of strong CYP3A4 inducers and tamoxifen. If the combination cannot be avoided, monitor for reduced therapeutic effects of tamoxifen.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Reduced concentrations of tamoxifen and its metabolites, in association with the administration of strong CYP3A4 inducers, have been described in several reports.<sup>1,2,3,4,5</sup> In a study conducted in 10 healthy volunteers, the AUC of tamoxifen (80 mg single dose) and its N-demethyltamoxifen metabolite decreased 86% and 62%, respectively, following a 5-day course of rifampin (600 mg once daily).<sup>1</sup> A pharmacokinetic study of 4 patients with breast cancer treated with tamoxifen (20 or 40 mg once daily) found a 28% to 85% reduction in the AUC of endoxifen, which is thought to be the most important metabolite contributing to the pharmacologic activity of tamoxifen, when followed by a 15-day course of rifampin (600 mg once daily).<sup>2</sup><br><br>These findings support the observations of a case report describing a 24% decrease in tamoxifen level (225.25 to 171.18 nM) following 10 days of rifampin (600 mg daily) therapy in a patient with breast cancer and ulcerative colitis.<sup>3</sup> In another report, a clinic observed an endoxifen level of 4.72 nmol/L, which is 7-fold lower than the mean seen in its patient population, in a patient concurrently taking tamoxifen (20 mg daily) and phenytoin.<sup>4</sup> Additionally, the tamoxifen prescribing information states that one patient receiving tamoxifen with concomitant phenobarbital exhibited a steady state serum level of tamoxifen lower than that observed for other patients (ie, 26 ng/mL vs mean value of 122 ng/mL).<sup>5</sup><br><br>Tamoxifen is a known substrate of several different cytochrome P450 enzymes, including CYP3A.<sup>5</sup> Induction of CYP3A4-mediated tamoxifen metabolism likely increases both tamoxifen clearance and the conversion of N-demethyltamoxifen to inactive metabolites. Since the therapeutic effects of tamoxifen appear to be dependent on formation of the major pharmacologically active metabolite endoxifen, a process catalyzed by CYP2D6,<sup>6</sup> the pharmacokinetic changes seen may therefore result in reduced tamoxifen efficacy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. <i>Clin Pharmacol Ther</i>. 1998;64(6):648-654. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9871429\">[PubMed 9871429]</a></p>\n<p>2. Binkhorst L, van Gelder T, Loos WJ, et al. Effects of CYP induction by rifampicin on tamoxifen exposure. <i>Clin Pharmacol Ther</i>. 2012;92(1):62-67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22617226\">[PubMed 22617226]</a></p>\n<p>3. Henderson SL, Teft WA, Kim RB. Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNF biologic for ulcerative colitis: a case report. <i>BMC Cancer</i>. 2016;16:304. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27169677\">[PubMed 27169677]</a></p>\n<p>4. Gryn SE, Teft WA, Kim RB. Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort. <i>Pharmacogenet Genomics</i>. 2014;24(7):367-369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24915025\">[PubMed 24915025]</a></p>\n<p>5. Soltamox (tamoxifen citrate) [prescribing information]. East Brunswick, NJ: Savient Pharmaceuticals Inc; August 2005.</p>\n<p>6. Brauch H, Murdter TE, Eichelbaum M, Schwab M. Pharmacogenomics of tamoxifen therapy. <i>Clin Chem</i>. 2009;55(10):1770-1782. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19574470\">[PubMed 19574470]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12039":"<p><b>Title</b> Lornoxicam / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Lornoxicam. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 12 healthy volunteers, the average maximum serum concentration and AUC of lornoxicam (8 mg daily) increased 28% and 9%, respectively, when coadministered with cimetidine (400 mg twice daily).<sup>1</sup> <br><br>Lornoxicam product labeling states that cimetidine may increase lornoxicam concentrations and effects.<sup>2</sup><br><br>The mechanism of this interaction is unknown but is possibly due to the inhibition of the hydroxylation of lornoxicam to 5’-hydroxylornoxicam by cimetidine, one of the major metabolic pathways of lornoxicam.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Xefo (lornoxicam) tablets [summary of product characteristics]. Riyadh, Saudi Arabia: Jazeera Pharmaceutical Industries (JPI); December 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12040":"<p><b>Title</b> Lornoxicam / CYP2C9 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2C9 Inducers (Moderate) may decrease the serum concentration of Lornoxicam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased lornoxicam efficacy if combined with CYP2C9 inducers.</p>\n<div>\n <p><b>CYP2C9 Inducers (Moderate) Interacting Members</b> Enzalutamide, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Several pharmacogenomic studies have evaluated the effect of CYP2C9 genotypes on lornoxicam exposure.<sup>1,2,3</sup> In poor metabolizers of CYP2C9, the lornoxicam AUC has been shown to be 60% to 103% higher than the lornoxicam AUC in extensive CYP2C9 metabolizers.<sup>1,2,3</sup> <br><br>The lornoxicam product labeling states that because CYP2C9 is primarily responsible for lornoxicam metabolism, CYP2C9 inducers may reduce lornoxicam serum concentrations and effects.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zhang Y, Zhong D, Si D, Guo Y, Chen X, Zhou H. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. <i>Br J Clin Pharmacol</i>. 2005;59(1):14-17. [PMID 15606435]</p>\n<p>2. Liu YL, Zhang W, Tan ZR, et al. Effect of the CYP2C9*3 allele on lornoxicam metabolism. <i>Clin Chim Acta</i>. 2006;364(1-2):287-291. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16182270\">[PubMed 16182270]</a></p>\n<p>3. Choi CI, Kim MJ, Jang CG, Park YS, Bae JW, Lee SY. Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam. <i>Basic Clin Pharmacol Toxicol</i>. 2011;109(6):476-480. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21726410\">[PubMed 21726410]</a></p>\n<p>4. Xefo (lornoxicam) tablets [summary of product characteristics]. Riyadh, Saudi Arabia: Jazeera Pharmaceutical Industries (JPI); December 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12041":"<p><b>Title</b> Erythromycin (Topical) / Isotretinoin (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Isotretinoin (Topical) may enhance the adverse/toxic effect of Erythromycin (Topical). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for skin irritation and other dermatological adverse effects (eg, erythema and epidermal peeling) with combined use of topical erythromycin and topical isotretinoin. If such adverse effects occur, reduce the frequency of applications. Consider discontinuing treatment and using alternate therapies if adverse effects persist.</p> \n<p><b>Discussion</b> Persistent irritation to the skin, such as Grade 3 erythema or epidermal peeling causing direct irritation to dermal layers, occurred in the majority of healthy subjects (35 out of 36) receiving topical erythromycin and isotretinoin (gel form) applied under an occlusive patch.<sup>1</sup> These adverse effects resulted in discontinuation for 35 out of 36 subjects by day 9 in a 3-week clinical study. Other treatment arms, erythomycin/tretinoin gel and erythromycin/tretinoin solution, also resulted in discontinuation for 35 out of 36 subjects by day 10 and day 11, respectively, compared with white petrolatum (control arm) and adapalene cream or gel, which exhibited only slight skin irritation.<sup>1</sup><br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Queille-Roussel C, Poncet M, Mesaros S, Clucas A, Baker M, Soloff AM. Comparison of the cumulative irritation potential of adapalene gel and cream with that of erythromycin/tretinoin solution and gel and erythromycin/isotretinoin gel. <i>Clin Ther.</i> 2001;23(2):205-212. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11293554\">[PubMed 11293554]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12043":"<p><b>Title</b> Lornoxicam / CYP2C9 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Lornoxicam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased lornoxicam effect/toxicities if combined with CYP2C9 inhibitors.</p>\n<div>\n <p><b>CYP2C9 Inhibitors (Moderate) Interacting Members</b> Fluconazole, MiFEPRIStone</p>\n</div> \n<p><b>Discussion</b> Several pharmacogenomic studies have evaluated the effect of CYP2C9 genotypes on lornoxicam exposure.<sup>1,2,3</sup> In poor metabolizers of CYP2C9, the lornoxicam AUC has been shown to be 60% to 103% higher than the lornoxicam AUC in extensive CYP2C9 metabolizers.<sup>1,2,3</sup> <br><br>The lornoxicam product labeling states that because CYP2C9 is primarily responsible for lornoxicam metabolism, CYP2C9 inhibitors may increase lornoxicam serum concentrations and effects.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zhang Y, Zhong D, Si D, Guo Y, Chen X, Zhou H. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. <i>Br J Clin Pharmacol</i>. 2005;59(1):14-17. [PMID 15606435]</p>\n<p>2. Liu YL, Zhang W, Tan ZR, et al. Effect of the CYP2C9*3 allele on lornoxicam metabolism. <i>Clin Chim Acta</i>. 2006;364(1-2):287-291. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16182270\">[PubMed 16182270]</a></p>\n<p>3. Choi CI, Kim MJ, Jang CG, Park YS, Bae JW, Lee SY. Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam. <i>Basic Clin Pharmacol Toxicol</i>. 2011;109(6):476-480. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21726410\">[PubMed 21726410]</a></p>\n<p>4. Xefo (lornoxicam) tablets [summary of product characteristics]. Riyadh, Saudi Arabia: Jazeera Pharmaceutical Industries (JPI); December 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12044":"<p><b>Title</b> Isotretinoin (Topical) / Benzoyl Peroxide</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Benzoyl Peroxide may diminish the therapeutic effect of Isotretinoin (Topical). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the combined use of benzoyl peroxide and topical isotretinoin as this may decrease the efficacy of isotretinoin. If these agents must be used concomitantly, consider separating application times of these agents (eg, morning vs evening). Monitor for signs and symptoms of potential clinical failure of isotretinoin.</p> \n<p><b>Discussion</b> According to international prescribing information, concomitant application of benzoyl peroxide and isotretinoin gel should be avoided as it may reduce the efficacy of isotretinoin.<sup>1</sup> To avoid possible clinical failure of isotretinoin, separate application times of these agents is recommended if combined therapy of benzoyl peroxide and isotretinoin is necessary.<sup>1</sup><br><br>The mechanism for this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Isotrex Gel (isotretinoin) [summary of product characteristics]. Brentford, Middlesex, United Kingdom: GlaxoSmithKline UK Limited; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12045":"<p><b>Title</b> Emedastine (Systemic) / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Emedastine (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for a possible increase in emedastine adverse effects (eg, sedation, cardiac arrhythmias) with concomitant ketoconazole administration.</p> \n<p><b>Discussion</b> The emedastine AUC increased approximately 33%, and the emedastine clearance decreased approximately 30% in the presence of ketoconazole according to a pharmacokinetic study of 12 healthy subjects who were given emedastine difumarate (4 mg orally daily) and ketoconazole (200 mg orally twice daily).<sup>1</sup> No clinically relevant adverse events (eg, QTc prolongation) were associated with the increased emedastine exposure, though this study is likely not sufficiently powered or optimally designed to provide a clear assessment of the clinical significance of these changes.<br><br>The emedastine product labeling cautions that care should be used during the coadministration of emedastine and ketoconazole due to the potential for increased adverse effects, including sedation and cardiac arrhythmias.<sup>2</sup> Emedastine is metabolized by multiple mechanisms, including CYP3A4 to a small extent. Due to the limited involvement of CYP3A4 in emedastine metabolism, a clinically significant interaction with ketoconazole is unlikely.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Herranz U, Rusca A, Assandri A. Emedastine-ketoconazole: pharmacokinetic and pharmacodynamic interactions in healthy volunteers. <i>Int J Clin Pharmacol Ther</i>. 2001 Mar;39(3):102-109. [PMID 11396749]</p>\n<p>2. Eurodastin SR (emedastine) capsule [UK summary of product characteristics]. Anagni, Italy: Geymonat S.P.A; July 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12047":"<p><b>Title</b> Pyrimethamine / LORazepam</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> LORazepam may enhance the hepatotoxic effect of Pyrimethamine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor liver function tests (eg, AST, ALT, total bilirubin) and other signs and symptoms of possible liver toxicity if lorazepam and pyrimethamine are coadministered.</p> \n<p><b>Discussion</b> A small trial of healthy women (n=5) demonstrated evidence of liver toxicity with coadministration of pyrimethamine (25 mg weekly up to 24 months) and lorazepam (2 mg daily for seven days).<sup>1</sup> Bilirubin and transaminases were significantly increased when both drugs were given concomitantly, but not when administered alone. The extent of these elevations of liver function tests were not reported. <sup>1</sup><br><br>Prescribing information warns of possible mild hepatotoxicity if this combination is used. Since the literature does not describe the full extent of this hepatotoxicity, liver function should be monitored if lorazepam and pyrimethamine are used together in patients.<sup>2</sup><br><br>The mechanism for this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Briggs M, Briggs M. Pyrimethamine toxicity. <i>Br Med J.</i> 1974; 1(5896): 40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4808828\">[PubMed 4808828]</a></p>\n<p>2. Daraprim (pyrimethamine). Turing Pharmaceuticals LLC, New York, NY; June 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12048":"<p><b>Title</b> QuiNINE / Nevirapine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nevirapine may decrease the serum concentration of QuiNINE. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of possible quinine clinical failure if combined with nevirapine. An increased dose of quinine may be considered. If quinine dose is adjusted, monitor for the toxicity potential of the quinine metabolite, 3-hydroxyquinone (3-HQN).</p> \n<p><b>Discussion</b> In a study of 14 healthy volunteers, nevirapine (200 mg every 12 hours for 12 days) decreased the quinine (600 mg single dose) AUC and maximum serum concentration (Cmax) 33% and 36%, respectively.<sup>1</sup> Decreased quinine trough concentrations were observed in HIV pregnant women (n=7) taking nevirapine-based antiretroviral therapy (ART) who were also being treated for uncomplicated malaria (positive smear test for <i>Plasmodium falciparum</i>).<sup>2</sup> Although quinine trough concentrations fell below the therapeutic range (5-15 mg/L) in 50% of patients, clinical failure did not occur and toxic effects due to increased metabolite concentrations of quinine were not reported.<sup>2</sup> Conversely, a case report describes an HIV-positive male on nevirapine-based ART diagnosed with malaria who experienced increased parasitemia (1% to 2.5%) during treatment with quinine.<sup>3</sup> Once quinine was switched to alternative therapy (atovaquone/proguanil), his parasitemia decreased and he made a full recovery.<sup>3</sup><br> <br>The mechanism of this interaction is likely due to nevirapine-mediated induction of the enzymes responsible for quinine metabolism (eg, CYP3A4).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, Cook JM. Effect of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. <i>J Pharm Pharmacol</i> 2009;61:439-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19298689\">[PubMed 19298689]</a></p>\n<p>2. Kayentao K, Guirou EA, Ogobara K, et al. Short report: Preliminary study of quinine pharmacokinetics in pregnant women with malaria-HIV co-infection. <i>Am J Trop Med Hyg.</i> 2014;90(3):530-534. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24420779\">[PubMed 24420779]</a></p>\n<p>3. Uriel A, Lewthwaite P. Malaria therapy in HIV: drug interactions between nevirapine and quinine. <i>Int J STD AIDS.</i> 2011;22(12): 768. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22174067\">[PubMed 22174067]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12049":"<p><b>Title</b> MetFORMIN / Colesevelam</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction is specific to the Metformin ER formulation.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Colesevelam may increase the serum concentration of MetFORMIN. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study summarized in the colesevelam prescribing information, simultaneous administration of colesevelam (3.75 g) with metformin ER (1,500 mg) increased metformin AUC and maximum concentration (Cmax) by 44% and 8%, respectively.<sup>1</sup> Colesevelam prescribing information states that patients receiving colesevelam and metformin ER concomitantly should be monitored for clinical response, as is usual for anti-diabetes drugs. The mechanism for this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Welchol (colesevelam hydrochloride) [prescribing information]. Parsippany, NJ: Daiichi Sankyo, Inc; January 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12050":"<p><b>Title</b> AtorvaSTATin / Colestipol</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Colestipol may decrease the serum concentration of AtorvaSTATin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study summarized in the atorvastatin prescribing information, simultaneous administration of colestipol (10 mg twice daily) with atorvastatin (40 mg daily) for 28 weeks resulted in a 26% decrease in atorvastatin maximum concentration (Cmax).<sup>1</sup> The mechanism for this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lipitor (atorvastatin calcium) [prescribing information]. New York, NY: Pfizer Inc; May 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12051":"<p><b>Title</b> Neuromuscular-Blocking Agents (Nondepolarizing) / Thiazide and Thiazide-Like Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thiazide and Thiazide-Like Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased neuromuscular-blocking effects if a nondepolarizing neuromuscular-blocking agent is coadministered with thiazide and thiazide-like diuretics.</p>\n<div>\n <p><b>Neuromuscular-Blocking Agents (Nondepolarizing) Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Vecuronium</p>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> The prescribing information for some products containing hydrochlorothiazide caution that the concomitant use of hydrochlorothiazide and nondepolarizing neuromuscular-blocking agents may increase the effects of neuromuscular-blocking agents.<sup>1,2,3,4</sup><br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Benicar HCT (olmesartan medoxomil and hydrochlorothiazide) [prescribing information]. Parsippany, NJ: Daiichi Sankyo, Inc; February 2016.</p>\n<p>2. Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide) [prescribing information]. Parsippany, NJ: Daiichi Sankyo, Inc; January 2017.</p>\n<p>3. Ziac (bisoprolol and hydrochlorothiazide) [prescribing information]. Pomona, NY: Duramed Pharmaceuticals, Inc; March 2011.</p>\n<p>4. Maxide (triamterene and hydrochlorothiazide) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; January 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12052":"<p><b>Title</b> Lesinurad / CYP2C9 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Lesinurad. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased lesinurad effects/toxicities when combined with moderate CYP2C9 inhibitors.</p>\n<div>\n <p><b>CYP2C9 Inhibitors (Moderate) Interacting Members</b> Fluconazole, MiFEPRIStone</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the lesinurad prescribing information, fluconazole (200 mg daily) increased the lesinurad AUC and maximum serum concentration approximately 60% and 40%, respectively.<sup>1</sup><br><br>Lesinurad prescribing information states that because lesinurad exposure is increased when coadministered with moderate inhibitors of CYP2C9 (ie, fluconazole), concomitant use should be done with caution and patients should be monitored for increased lesinurad toxicities.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zurampic (lesinurad) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12053":"<p><b>Title</b> Lesinurad / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Amiodarone may increase the serum concentration of Lesinurad. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the lesinurad prescribing information, the moderate CYP2C9 inhibitor fluconazole (200 mg daily) increased the lesinurad AUC and maximum serum concentration approximately 60% and 40%, respectively.<sup>1</sup><br><br>Lesinurad prescribing information states that because lesinurad exposure is increased when coadministered with moderate inhibitors of CYP2C9 (ie, fluconazole), concomitant use should be done with caution and patients should be monitored for increased lesinurad toxicities.<sup>1</sup> Although the prescribing information lists amiodarone as an example of a moderate CYP2C9 inhibitor, available clinical data suggest that amiodarone is a weak CYP2C9 inhibitor.<sup>2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zurampic (lesinurad) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2015.</p>\n<p>2. Heimark LD, Wienkers L, Kunze K, et al. The mechanism of the interaction between amiodarone and warfarin in humans. <i>Clin Pharmacol Ther</i>. 1992;51(4):398-407. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1563209\">[PubMed 1563209]</a></p>\n<p>3. Nolan PE Jr, Erstad BL, Hoyer GL, Bliss M, Gear K, Marcus FI. Steady-state interaction between amiodarone and phenytoin in normal subjects. <i>Am J Cardiol</i>. 1990;65(18):1252-1257. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2337037\">[PubMed 2337037]</a></p>\n<p>4. Nolan PE Jr, Marcus FI, Hoyer GL, Bliss M, Gear K. Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. <i>Clin Pharmacol Ther</i>. 1989;46(1):43-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2743707\">[PubMed 2743707]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12054":"<p><b>Title</b> Nateglinide / CYP2C9 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Nateglinide. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients for increased nateglinide effects (eg, hypoglycemia) if combined with moderate CYP2C9 inhibitors.</p>\n<div>\n <p><b>CYP2C9 Inhibitors (Moderate) Interacting Members</b> Fluconazole, MiFEPRIStone</p>\n</div> \n<p><b>Discussion</b> The AUC of nateglinide (30 mg single dose) increased 48% in 10 healthy volunteers when administered following a 4-day course of the moderate CYP2C9 inhibitor fluconazole (400 mg on day 1, 200 mg thereafter).<sup>1</sup> The M7 metabolite maximum serum concentrations (Cmax) decreased 34%, while the nateglinide Cmax remained unchanged. Although there were no changes in the hypoglycemic effects of nateglinide in this study, subtherapeutic doses of nateglinide were used.<sup>1</sup> <br><br>The prescribing information for nateglinide states that CYP2C9 inhibitors may potentiate the hypoglycemic action of nateglinide and patients should be closely monitored for changes in blood glucose.<sup>2</sup><br><br>The mechanism of this potential interaction is likely due to fluconazole-mediated inhibition of CYP2C9, an enzyme primarily responsible for nateglinide metabolism. Fluconazole-mediated inhibition of CYP3A4 may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Niemi M, Neuvonen M, Juntti-Patinen L, Backman JT, Neuvonen PJ. Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide. <i>Clin Pharmacol Ther</i>. 2003;74(1):25-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12844132\">[PubMed 12844132]</a> </p>\n<p>2. Starlix (nateglinide) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation: March 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12055":"<p><b>Title</b> Nateglinide / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Amiodarone may increase the serum concentration of Nateglinide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The AUC of nateglinide (30 mg single dose) increased 48% in 10 healthy volunteers when administered following a 4-day course of the moderate CYP2C9 inhibitor fluconazole (400 mg on day 1, 200 mg thereafter).<sup>1</sup> The M7 metabolite maximum serum concentrations (Cmax) decreased 34%, while the nateglinide Cmax remained unchanged. Although there were no changes in the hypoglycemic effects of nateglinide in this study, subtherapeutic doses of nateglinide were used.<sup>1</sup> <br><br>The prescribing information for nateglinide states that CYP2C9 inhibitors may potentiate the hypoglycemic action of nateglinide and patients should be closely monitored for changes in blood glucose.<sup>2</sup> Although the prescribing information lists amiodarone as a CYP2C9 inhibitor similar to fluconazole, the clinical data suggest amiodarone is only a weak CYP2C9 inhibitor and may have substantially less of an impact on nateglinide exposure.<sup>2,3,4</sup> <br><br>The mechanism of this potential interaction is likely due to fluconazole-mediated inhibition of CYP2C9, an enzyme primarily responsible for nateglinide metabolism. Fluconazole-mediated inhibition of CYP3A4 may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Starlix (nateglinide) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation: March 2017.</p>\n<p>2. Heimark LD, Wienkers L, Kunze K, et al. The mechanism of the interaction between amiodarone and warfarin in humans. <i>Clin Pharmacol Ther</i>. 1992;51(4):398-407. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1563209\">[PubMed 1563209]</a></p>\n<p>3. Nolan PE Jr, Erstad BL, Hoyer GL, Bliss M, Gear K, Marcus FI. Steady-state interaction between amiodarone and phenytoin in normal subjects. <i>Am J Cardiol</i>. 1990;65(18):1252-1257. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2337037\">[PubMed 2337037]</a></p>\n<p>4. Nolan PE Jr, Marcus FI, Hoyer GL, Bliss M, Gear K. Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. <i>Clin Pharmacol Ther</i>. 1989;46(1):43-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2743707\">[PubMed 2743707]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12056":"<p><b>Title</b> Nateglinide / Sulfinpyrazone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Sulfinpyrazone may increase the serum concentration of Nateglinide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The AUC of nateglinide (30 mg single dose) increased 48% in 10 healthy volunteers when administered following a 4-day course of the moderate CYP2C9 inhibitor fluconazole (400 mg on day 1, 200 mg thereafter).<sup>1</sup> The M7 metabolite maximum serum concentrations (Cmax) decreased 34%, while the nateglinide Cmax remained unchanged. Although there were no changes in the hypoglycemic effects of nateglinide in this study, subtherapeutic doses of nateglinide were used.<sup>1</sup> <br><br>The prescribing information for nateglinide states that CYP2C9 inhibitors may potentiate the hypoglycemic action of nateglinide and patients should be closely monitored for changes in blood glucose.<sup>2</sup> Although the prescribing information lists sulfinpyrazone as a CYP2C9 inhibitor similar to fluconazole, the clinical data suggest sulfinpyrazone is only a weak CYP2C9 inhibitor and may have substantially less of an impact on nateglinide exposure.<sup>2,3,4</sup> <br><br>The mechanism of this potential interaction is likely due to fluconazole-mediated inhibition of CYP2C9, an enzyme primarily responsible for nateglinide metabolism. Fluconazole-mediated inhibition of CYP3A4 may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Starlix (nateglinide) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation: March 2017.</p>\n<p>2. Toon S, Low LK, Gibaldi M, et al. The warfarin-sulfinpyrazone interaction: stereochemical considerations. <i>Clin Pharmacol Ther</i>. 1986;39(1):15-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3943265\">[PubMed 3943265]</a></p>\n<p>3. Miners JO, Foenander T, Wanwimolruk S, Gallus AS, Birkett DJ. The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination. <i>Eur J Clin Pharmacol</i>. 1982;22(4):321-326. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7106168\">[PubMed 7106168]</a></p>\n<p>4. O'Reilly RA. Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man. <i>Circulation</i>. 1982;65(1):202-207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7053283\">[PubMed 7053283]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12057":"<p><b>Title</b> Nateglinide / Voriconazole</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Voriconazole may increase the serum concentration of Nateglinide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The AUC of nateglinide (30 mg single dose) increased 48% in 10 healthy volunteers when administered following a 4-day course of the moderate CYP2C9 inhibitor fluconazole (400 mg on day 1, 200 mg thereafter).<sup>1</sup> The M7 metabolite maximum serum concentrations (Cmax) decreased 34%, while the nateglinide Cmax remained unchanged. Although there were no changes in the hypoglycemic effects of nateglinide in this study, subtherapeutic doses of nateglinide were used.<sup>1</sup> <br><br>The prescribing information for nateglinide states that CYP2C9 inhibitors may potentiate the hypoglycemic action of nateglinide and patients should be closely monitored for changes in blood glucose.<sup>2</sup> Although the prescribing information lists voriconazole as a CYP2C9 inhibitor similar to fluconazole, the clinical data suggest voriconazole is only a weak CYP2C9 inhibitor and may have substantially less of an impact on nateglinide exposure.<sup>2,3,4</sup> <br><br>The mechanism of this potential interaction is likely due to fluconazole-mediated inhibition of CYP2C9, an enzyme primarily responsible for nateglinide metabolism. Fluconazole-mediated inhibition of CYP3A4 may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Starlix (nateglinide) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation: March 2017.</p>\n<p>2. Bosilkovska M, Samer CF, Deglon J, et al. Geneva cocktail for cytochrome P450 and P-glycoprotein activity assessment using dried blood spots. <i>Clin Pharmacol Ther</i>. 2014;96(3):349-359. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24722393\">[PubMed 24722393]</a></p>\n<p>3. Hynninen VV, Olkkola KT, Leino K, et al. Effect of voriconazole on the pharmacokinetics of diclofenac. <i>Fundam Clin Pharmacol</i>. 2007;21(6):651-656. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18034666\">[PubMed 18034666]</a></p>\n<p>4. Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. <i>Br J Clin Pharmacol</i>. 2003;56(suppl 1):37-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14616412\">[PubMed 14616412]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12058":"<p><b>Title</b> Torsemide / CYP2C9 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Torsemide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased torsemide effects/toxicities if combined with moderate CYP2C9 inhibitors. Adjust torsemide dosing as needed.</p>\n<div>\n <p><b>CYP2C9 Inhibitors (Moderate) Interacting Members</b> Fluconazole, MiFEPRIStone</p>\n</div> \n<p><b>Discussion</b> Torsemide prescribing information states that because torsemide is metabolized by CYP2C9, use of moderate CYP2C9 inhibitors may decrease torsemide clearance and increase torsemide plasma concentrations.<sup>1</sup> No clinical studies have evaluated the use of CYP2C9 inhibitors on torsemide exposure or effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Demadex (torsemide) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc; February 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12059":"<p><b>Title</b> Torsemide / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Amiodarone may increase the serum concentration of Torsemide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Torsemide prescribing information states that because torsemide is metabolized by CYP2C9, use of CYP2C9 inhibitors may decrease torsemide clearance and increase torsemide plasma concentrations.<sup>1</sup> No clinical studies have evaluated the use of CYP2C9 inhibitors on torsemide exposure or effects. Amiodarone is only a weak CYP2C9 inhibitor and is unlikely to have clinically significant effects on torsemide exposure.<sup>2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Demadex (torsemide) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc; February 2017.</p>\n<p>2. Heimark LD, Wienkers L, Kunze K, et al. The mechanism of the interaction between amiodarone and warfarin in humans. <i>Clin Pharmacol Ther</i>. 1992;51(4):398-407. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1563209\">[PubMed 1563209]</a></p>\n<p>3. Nolan PE Jr, Erstad BL, Hoyer GL, Bliss M, Gear K, Marcus FI. Steady-state interaction between amiodarone and phenytoin in normal subjects. <i>Am J Cardiol</i>. 1990;65(18):1252-1257. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2337037\">[PubMed 2337037]</a></p>\n<p>4. Nolan PE Jr, Marcus FI, Hoyer GL, Bliss M, Gear K. Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy subjects. <i>Clin Pharmacol Ther</i>. 1989;46(1):43-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2743707\">[PubMed 2743707]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12060":"<p><b>Title</b> Torsemide / Oxandrolone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Oxandrolone may increase the serum concentration of Torsemide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Torsemide prescribing information states that because torsemide is metabolized by CYP2C9, use of CYP2C9 inhibitors may decrease torsemide clearance and increase torsemide plasma concentrations.<sup>1</sup> No clinical studies have evaluated the use of CYP2C9 inhibitors on torsemide exposure or effects. Although oxandrolone is listed as an example of a CYP2C9 inhibitor in the torsemide prescribing information, it is unclear if oxandrolone is a clinically relevant inhibitor of CYP2C9.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Demadex (torsemide) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc; February 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12061":"<p><b>Title</b> Warfarin / Etravirine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Etravirine may increase the serum concentration of Warfarin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, etravirine (200 mg twice daily for 14 days) coadministered with warfarin (10 mg single dose) had no effect on the S-warfarin AUC or maximum serum concentration.<sup>1</sup> However, the 7-OH-S-warfarin metabolite AUC decreased 42%, suggesting metabolism of S-warfarin was altered in the presence of etravirine.<sup>1</sup><br><br>Etravirine prescribing information states that warfarin concentrations may be increased when coadministered with etravirine and that the international normalized ratio (INR) should be monitored when these agents are combined.<sup>1</sup><br><br>The mechanism of this potential interaction has not been fully investigated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Intelence (etravirine) [prescribing information]. Titusville NJ: Janssen Therapeutics; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12062":"<p><b>Title</b> Zafirlukast / CYP2C9 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Zafirlukast. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>CYP2C9 Inhibitors (Moderate) Interacting Members</b> Fluconazole, MiFEPRIStone</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, fluconazole (400 mg once, followed by 200 mg daily for 4 days) increased the zafirlukast (20 mg single dose) AUC and maximum serum concentration 58% and 54%, respectively.<sup>1,2</sup><br><br>The zafirlukast prescribing information states that although CYP2C9 inhibitors are likely to increase exposure of zafirlukast, the clinical significance of this interaction is unclear.<sup>2</sup><br><br>The mechanism is likely due to fluconazole-mediated inhibition of CYP2C9, an enzyme responsible for zafirlukast metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Karonen T, Laitila J, Niemi M, Neuvonen PJ, Backman JT. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. <i>Eur J Clin Pharmacol</i>. 2012;68(5):681-688. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22108774\">[PubMed 22108774]</a></p>\n<p>2. Accolate (zafirlukast) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12063":"<p><b>Title</b> Vitamin K Antagonists / Floxuridine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Floxuridine may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor INR and signs/symptoms of bleeding closely when starting or stopping floxuridine in a patient receiving a vitamin K antagonist. Anticoagulant dose adjustment will likely be necessary.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> Although no studies describe the effects of floxuridine on vitamin K antagonists, several case reports describe marked increases in PT/INR, accompanied by bleeding, in warfarin-stable patients following the administration of fluorouracil, which is the active metabolite of floxuridine.<sup>1,2,3,4,5,6,7</sup> One report demonstrated the effects of a regimen containing fluorouracil and levamisole upon both dechallenge and rechallenge of the patient.<sup>6</sup> The lack of reports related to levamisole suggest that the fluorouracil was the causative agent. <br><br>The mechanism of this interaction appears to fluorouracil-mediated inhibition of S-warfarin (most potent enantiomer) metabolism. Though fluorouracil does not appear to have any direct inhibitory effect on CYP2C9 in microsomal studies,<sup>8,9</sup> studies in rats and patients with colorectal cancer have demonstrated decreased CYP2C9 activity (i.e., phenytoin hydroxylation<sup>8</sup> and losartan/E3174 ratio<sup>10</sup>) following fluorouracil treatment. Of note, the inhibition appears time- and/or dose-dependent with greater inhibition after 3 cycles of fluorouracil (5.3-fold decrease) than after 1 cycle (28% decrease).<sup>10</sup> An observation that the warfarin dose reductions required during fluorouracil therapy increase with each cycle of fluorouracil further support this time-/dose-dependence.<sup>11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Booth BW, Weiss RB. Venous thrombosis during adjuvant chemotherapy. <i>N Engl J Med</i>. 1981;305(3):170. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7242590\">[PubMed 7242590]</a></p>\n<p>2. Seifter EJ, Brooks BJ Jr, Urba WJ. Possible interactions between warfarin and antineoplastic drugs. <i>Cancer Treat Rep</i>. 1985;69(2):244-245. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3971397\">[PubMed 3971397]</a></p>\n<p>3. Wajima T, Mukhopadhyay P. Possible interactions between warfarin and 5-fluorouracil. <i>Am J Hematol</i>. 1992;40(3):238-243. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1609780\">[PubMed 1609780]</a></p>\n<p>4. Chelobowski RT, Gota CH, Chann KK, Weiner JM, Block JB, Bateman JR. Clinical and pharmacokinetic effects on combined warfarin and 5-fluorouracil in advanced colon cancer. <i>Cancer Res</i>. 1982;42(11):4827-4830. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7127318\">[PubMed 7127318]</a></p>\n<p>5. Brown MC. Multisite mucous membrane bleeding due to a possible interaction between warfarin and 5-fluorouracil. <i>Pharmacotherapy</i>. 1997;17(3):631-633. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9165571\">[PubMed 9165571]</a></p>\n<p>6. Scarfe MA, Israel MK. Possible drug interaction between warfarin and combination of levamisole and fluorouracil. <i>Ann Pharmacother</i>. 1994;28(4):464-467. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8038468\">[PubMed 8038468]</a></p>\n<p>7. Kolesar JM, Johnson CL, Freeberg BL, Berlin JD, Schiller JH. Warfarin-5-FU interaction--a consecutive case series. <i>Pharmacotherapy</i>. 1999;19(12):1445-1449. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10600095\">[PubMed 10600095]</a></p>\n<p>8. Konishi H, Yoshimoto T, Morita K, Minouchi T, Sato T, Yamaji A. Depression of phenytoin metabolic capacity by 5-fluorouracil and doxifluridine in rats. <i>J Pharm Pharmacol</i>. 2003;55(1):143-149. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12625878\">[PubMed 12625878]</a></p>\n<p>9. Park JY, Kim KA. Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes. <i>Eur J Clin Pharmacol</i>. 2003;59(5-6):407-409. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12904931\">[PubMed 12904931]</a></p>\n<p>10. Gunes A, Coskun U, Boruban C, et al. Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients. <i>Basic Clin Pharmacol Toxicol</i>. 2006;98(2):197-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16445595\">[PubMed 16445595]</a></p>\n<p>11. Davis DA, Fugate SE. Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5-fluorouracil therapy. <i>Pharmacotherapy</i>. 2005;25(3):442-447. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15843293\">[PubMed 15843293]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12064":"<p><b>Title</b> Floxuridine / MetroNIDAZOLE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> MetroNIDAZOLE (Systemic) may increase serum concentrations of the active metabolite(s) of Floxuridine. Specifically, serum concentrations of fluorouracil may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for evidence of adverse floxuridine effects (eg, hematologic, stomatitis, others) if metronidazole is used concurrently.</p> \n<p><b>Discussion</b> The AUC of fluorouracil (the active moiety of floxuridine) was increased by an average of 34% in a study of 27 patients with metastatic colorectal cancer when metronidazole (750 mg/m<sup>2</sup> IV) was given 1 hour prior to fluorouracil (600 mg/m<sup>2</sup> IV) for 5 consecutive days.<sup>1</sup> Several toxic effects of fluorouracil were also noted to be increased with concurrent metronidazole, including granulocytopenia, anemia, thrombocytopenia, stomatitis, and nausea/vomiting.<br><br>A published letter also describes increased fluorouracil-associated neutropenia in a pilot trial in which subjects received concurrent metronidazole as compared with a previous pilot trial in which subjects received an identical fluorouracil regimen but without concurrent metronidazole (4/12 subjects vs. 0/20 subjects with neutropenia, respectively).<sup>2</sup> A study in mice also describes some increase in fluorouracil toxicity with concurrent metronidazole.<sup>3</sup><br><br>The specific mechanism(s) for this interaction is uncertain. Metronidazole treatment was associated with an average 27% reduction in 5-fluorouracil clearance,<sup>1</sup> suggesting that metronidazole may interfere with 5-fluorouracil metabolism and/or elimination, but the precise mechanism(s) by which this occurs is not clear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bardakji Z, Jolivet J, Langelier Y, Besner JG, Ayoub J. 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Clinical, pharmacokinetic and in vitro cytotoxicity studies. <i>Cancer Chemother Pharmacol</i>. 1986;18(2):140-144. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3791559\">[PubMed 3791559]</a></p>\n<p>2. Windle R, Macpherson S, Bell PR. Neutropenia associated with metronidazole. <i>Br Med J</i>. 1979;2(6199):1219. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=519366\">[PubMed 519366]</a></p>\n<p>3. Tannock IF. In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: methotrexate, 5-fluorouracil and adriamycin. <i>Br J Cancer</i>. 1980;42(6):861-870. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7459220\">[PubMed 7459220]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12065":"<p><b>Title</b> Floxuridine / Leucovorin Calcium-Levoleucovorin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Floxuridine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Enhanced response to floxuridine, including the potential for greater toxicity, is to be expected with this combination. Monitor closely for floxuridine toxicities, including diarrhea, mucositis/stomatitis, and neutropenia.</p>\n<div>\n <p><b>Leucovorin Calcium-Levoleucovorin Interacting Members</b> Leucovorin Calcium, LEVOleucovorin</p>\n</div> \n<p><b>Discussion</b> Prescribing information for leucovorin calcium and levoleucovorin caution that these agents can enhance the toxicity of 5-fluorouracil (the active moiety of floxuridine).<sup>1,2</sup> This interaction is used clinically in the treatment of specific cancers in an attempt to enhance the anti-tumor effects of 5-fluorouracil, with studies of different dosing regimens attempting to find ways of maximizing the anti-tumor effects of the combination while minimizing the risk of excessive toxicity.<sup>3,4</sup> Some data suggest that weekly administration of high-dose leucovorin calcium results in less toxicity (primary toxicity with this regimen is diarrhea) than daily (for 5 days) administration of leucovorin calcium, which is associated with multiple toxicities including mucositis, diarrhea, and neutropenia.<sup>3,4</sup><br><br>The mechanism of this interaction involves the conversion of leucovorin or levoleucovorin to the reduced folate 5,10-methylenetetrahydrofolate (CH<sub>2</sub>FH<sub>4</sub>), which then works to stabilize the binding of fluorodeoxyuridine (FdUMP; produced from 5-fluorouracil) to its target, thymidylate synthase.<sup>3,4</sup> FdUMP (ie, 5-fluorouracil) is more cytotoxic in the presence of CH<sub>2</sub>FH<sub>4</sub> as a result of this enhanced formation/stability of the thymidylate synthase-FdUMP-CH<sub>2</sub>FH<sub>4</sub> complex. Both enhanced anti-tumor effects and greater toxicity of 5-fluorouracil in combination with leucovorin calcium/levoleucovorin result from this same mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Leucovorin calcium [prescribing information]. Bedford, OH: Bedford Laboratories; September 2000.</p>\n<p>2. Levoleucovorin [prescribing information]. Irvine, CA: Spectrum Pharmaceuticals Inc; 2008.</p>\n<p>3. Rustum YM, Cao S, Zhang Z. Rationale for treatment design: biochemical modulation of 5-fluorouracil by leucovorin. <i>Cancer J Sci Am</i>. 1998;4(1):12-18. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9467039\">[PubMed 9467039]</a></p>\n<p>4. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. <i>Cancer</i>. 1997;80(7):1179-1187. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9317168\">[PubMed 9317168]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12066":"<p><b>Title</b> Diclofenac (Systemic) / CYP2C9 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Diclofenac (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider using a reduced dose of diclofenac when used together with moderate CYP2C9 inhibitors. Arthrotec (diclofenac and misoprostol) prescribing information recommends a maximum dose of 50 mg twice daily when coadministered with CYP2C9 inhibitors. When this combination is used, monitor for increased effects/toxicity of diclofenac (eg, gastrointestinal bleeding, renal impairment).</p>\n<div>\n <p><b>CYP2C9 Inhibitors (Moderate) Interacting Members</b> Fluconazole, MiFEPRIStone</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 10 healthy male volunteers, the AUC and maximum serum concentration of diclofenac (50 mg single dose on day 2) increased 78% and 114%, respectively, and renal clearance decreased 47%, when coadministered with voriconazole (400 mg twice daily on day 1 followed by 200 mg twice daily on day 2).<sup>1</sup><br><br>Arthrotec (diclofenac and misoprostol) prescribing information recommends that doses should not exceed 50 mg twice daily when coadministered with CYP2C9 inhibitors.<sup>2</sup> Prescribing information for other diclofenac products does not recommend a specific diclofenac dose limit, but does recommend consideration of a diclofenac dose reduction when used concurrently with CYP2C9 inhibitors.<sup>3,4,5</sup><br><br>The likely mechanism of this interaction is inhibition of CYP2C9-mediated metabolism of diclofenac by voriconazole.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hynninen VV, Olkkola KT, Leino K. Effect of voriconazole on the pharmacokinetics of diclofenac. <i>Fundam Clin Pharmacol</i>. 2007;21(6):651-656. [PMID 18034666]</p>\n<p>2. Arthrotec (diclofenac/misoprostol) [prescribing information]. New York, NY: Pfizer Inc; September 2014.</p>\n<p>3. Voltaren XR (diclofenac sodium extended-release) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2011.</p>\n<p>4. Cataflam (diclofenac potassium) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2011.</p>\n<p>5. Dyloject (diclofenac sodium) [prescribing information]. Lake Forest, IL: Hospira Inc; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12067":"<p><b>Title</b> Fosphenytoin-Phenytoin / Sulfinpyrazone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sulfinpyrazone may increase the serum concentration of Fosphenytoin-Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased phenytoin serum concentrations and effects if combined with sulfinpyrazone.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> Sulfinpyrazone product labeling states that sulfinpyrazone may decrease the metabolism of phenytoin and possibly displace phenytoin from protein-binding sites, which may increase phenytoin plasma concentrations.<sup>1</sup> While the effects of sulfinpyrazone on phenytoin exposure has not been evaluated in a clinical study, sulfinpyrazone is a weak inhibitor of CYP2C9,<sup>2,3,4</sup> an enzyme partially responsible for phenytoin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Anturan (sulfinpyrazone) [summary of product characteristics]. London, United Kingdom: Amidpharm UK Limited; August 2016.</p>\n<p>2. Toon S, Low LK, Gibaldi M, et al. The warfarin-sulfinpyrazone interaction: stereochemical considerations. <i>Clin Pharmacol Ther</i>. 1986;39(1):15-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3943265\">[PubMed 3943265]</a></p>\n<p>3. Miners JO, Foenander T, Wanwimolruk S, Gallus AS, Birkett DJ. The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination. <i>Eur J Clin Pharmacol</i>. 1982;22(4):321-326. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7106168\">[PubMed 7106168]</a></p>\n<p>4. O'Reilly RA. Steroselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man. <i>Circulation</i>. 1982;65(1):202-207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7053283\">[PubMed 7053283]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12068":"<p><b>Title</b> GlyBURIDE / SORAfenib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> SORAfenib may enhance the hypoglycemic effect of GlyBURIDE. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for hypoglycemia if sorafenib and glyburide are combined.</p> \n<p><b>Discussion</b> One case report describes a 70-year-old man on a stable dose of glyburide (3.5 mg twice daily) who experienced severe hypoglycemia (blood glucose 37 mg/dL), disorientation, and somnolence after one dose of sorafenib (800 mg).<sup>1</sup><br><br>The mechanism of this potential interaction has not been fully investigated, but decreased blood sugar concentrations and hypoglycemia have been attributed to sorafenib use,<sup>2,3</sup> so additive hypoglycemic effects of each agent may have contributed to severe hypoglycemia in this patient. Sorafenib-mediated inhibition of glyburide metabolism may also have played a role.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Holstein A, Kovacs P, Beil W. Severe hypoglycemia due to possible interaction between glibenclamide and sorafenib in a patient with hepatocellular carcinoma. <i>Curr Drug Saf</i>. 2013;8(2):148-152. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23845193\">[PubMed 23845193]</a></p>\n<p>2. Agostino NM, Chinchilli VM, Lynch CJ, et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general practice. <i>J Oncol Pharm Pract</i>. 2011;17(3):197-202. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20685771\">[PubMed 20685771]</a></p>\n<p>3. Lee SW, Lee EK, Yun T, et al. Recurrent hypoglycemia triggered by sorafenib therapy in a patient with hemangiopericytoma. <i>Endocrinol Metab (Seoul)</i>. 2014;29(2):202-205. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25031894\">[PubMed 25031894]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12069":"<p><b>Title</b> Quinolones / Angiotensin-Converting Enzyme Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Angiotensin-Converting Enzyme Inhibitors may enhance the arrhythmogenic effect of Quinolones. Quinolones may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action needed. If ACE inhibitors and fluoroquinolones are used concomitantly in patients with other risk factors for either acute kidney injury or arrhythmias, more frequent monitoring of renal function or cardiac rhythm may be appropriate.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin</p>\n</div> \n<p><b>Discussion</b> The risk for acute kidney injury (AKI) was 4.5-fold higher with coadministration of quinolone antibiotics and ACE inhibitors in a nested-case control study of 1,292 older men who were admitted the hospital for AKI and 12,651 matched controls admitted for another reason.<sup>1</sup> Results were relatively similar with angiotensin receptor blockers. Consistent with these findings, a review of VigiBase, the WHO global database of individual case safety reports, identified 11 reports of AKI where the authors concluded that ciprofloxacin alone or an interaction between enalapril and ciprofloxacin was the most likely explanation for their AKI.<sup>2</sup> However, many other risk factors for AKI were present prior to initiation of ciprofloxacin in many of these cases, including use of other nephrotoxic agents (NSAIDs, diuretics), age greater than 80 years, history of renal failure, and urinary tract infection, making it difficult to determine what role, if any, an interaction between ciprofloxacin and enalapril played in these cases. The precise mechanism by which a quinolone and an ACE inhibitor would interact to cause AKI is unknown. Fluoroquinolones and ACE inhibitors have each been independently associated with AKI, though the risks are likely via different mechanisms.<br><br>Additionally, a population-based retrospective study in patients age 66 and older who were receiving an ACE inhibitor or angiotensin receptor blockers (ARB) and died of sudden death within 14 days of receiving a prescription for various antibiotics showed that concomitant administration of an ACE inhibitor or ARB with the quinolone ciprofloxacin was associated with increased odds of sudden death when compared with amoxicillin [adjusted OR=1.3 (95% CI: 1.03 to 1.6)].<sup>3</sup> In a similar study by the same group, concurrent use of ciprofloxacin with spironolactone was associated with an increased odds of sudden death when compared with amoxicillin [adjusted OR=1.6 (95% CI: 1.02 to 2.4)].<sup>4</sup> An additional sensitivity analysis, for which individuals were matched by disease risk index, resulted in a loss of statistical significance but only slightly lessened the increase in odds [adjusted OR=1.4 (95% CI: 0.7 to 2.7)]. The mechanism for this purported interaction is uncertain, but it has been suggested that the combination of ciprofloxacin, which has been associated with prolongation of the QT interval and possible proarrhythmic effects, with a drug capable of causing hyperkalemia (eg, spironolactone, other drugs acting on the renin-angiotensin-aldosterone system, etc.) may further increase the risk for dangerous proarrhythmic effects.<sup>3,4</sup> Other quinolones such as levofloxacin, gemifloxacin, moxifloxacin, and sparfloxacin have also been shown to have QT-prolonging effects, suggesting any risk would extend to these quinolones.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bird ST, Etminan M, Brophy JM, Hartzema AG, Delaney JA. Risk of acute kidney injury associated with the use of fluoroquinolones. <i>CMAJ</i>. 2013;185(10):E475-482. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23734036\">[PubMed 23734036]</a></p>\n<p>2. Savage R. Ciprofloxacin, enalapril and acute kidney injury: strengthening of a drug interaction signal. <i>WHO Pharmaceuticals Newsletter</i>. 2018;1:16-21.</p>\n<p>3. Fralick M, Macdonald EM, Gomes T, et al. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. <i>BMJ</i>. 2014;349:g6196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25359996\">[PubMed 25359996]</a></p>\n<p>4. Antoniou T, Hollands S, Macdonald EM, Gomes T, Mamdani MM, Juurlink DN, Canadian Drug Safety and Effectiveness Research Network. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. <i>CMAJ</i>. 2015;187(4):E138-E143. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25646289\">[PubMed 25646289]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12070":"<p><b>Title</b> Quinolones / Angiotensin II Receptor Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Angiotensin II Receptor Blockers may enhance the arrhythmogenic effect of Quinolones. Quinolones may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required. If angiotensin receptor blockers and quinolones are used concomitantly in patients with other risk factors for either acute kidney injury or arrhythmias, more frequent monitoring of renal function or cardiac rhythm may be appropriate.</p>\n<div>\n <p><b>Angiotensin II Receptor Blockers Interacting Members</b> Azilsartan, Candesartan, Eprosartan, Fimasartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan</p>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin</p>\n</div> \n<p><b>Discussion</b> The risk for acute kidney injury (AKI) was 3.8-fold higher with coadministration of quinolone antibiotics and angiotensin receptor blockers (ARBs) in a nested-case control study of 1,292 older men who were admitted the hospital for AKI and 12,651 matched controls admitted for another reason.<sup>1</sup> Results were relatively similar with angiotensin-converting enzyme (ACE) inhibitors. Consistent with these findings, a review of VigiBase, the WHO global database of individual case safety reports, identified 11 reports of AKI where the authors concluded that ciprofloxacin alone or an interaction between the ACE inhibitor enalapril and the quinolone ciprofloxacin was the most likely explanation for their AKI.<sup>2</sup> However, many other risk factors for AKI were present prior to initiation of ciprofloxacin in many of these cases, including use of other nephrotoxic agents (NSAIDs, diuretics), age greater than 80 years, history of renal failure, and urinary tract infection, making it difficult to determine what role, if any, an interaction between ciprofloxacin and enalapril played in these cases. The precise mechanism by which a quinolone and an ARB would interact to cause AKI is unknown. Fluoroquinolones and ARBs have each been independently associated with AKI, though the risks are likely via different mechanisms.<br><br>Additionally, a population-based retrospective study in patients age 66 and older who were receiving an ACE inhibitor or ARB and died of sudden death within 14 days of receiving a prescription for various antibiotics showed that concomitant administration of an ACE inhibitor or ARB with ciprofloxacin was associated with increased odds of sudden death when compared with amoxicillin [adjusted OR=1.3 (95% CI: 1.03 to 1.6)].<sup>3</sup> In a similar study by the same group, concurrent use of ciprofloxacin with spironolactone was associated with an increased odds of sudden death when compared with amoxicillin [adjusted OR=1.6 (95% CI: 1.02 to 2.4)].<sup>4</sup> An additional sensitivity analysis, for which individuals were matched by disease risk index, resulted in a loss of statistical significance but only slightly lessened the increase in odds [adjusted OR=1.4 (95% CI: 0.7 to 2.7)].<br><br>The mechanism for this purported interaction is uncertain, but it has been suggested that the combination of ciprofloxacin, which has been associated with prolongation of the QT interval and possible proarrhythmic effects, with a drug capable of causing hyperkalemia (eg, spironolactone, other drugs acting on the renin-angiotensin-aldosterone system, etc.) may further increase the risk for dangerous proarrhythmic effects.<sup>3,4</sup> Other quinolones such as levofloxacin, gemifloxacin, moxifloxacin, and sparfloxacin have also been shown to have QT-prolonging effects, suggesting any risk would extend to these quinolones.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bird ST, Etminan M, Brophy JM, Hartzema AG, Delaney JA. Risk of acute kidney injury associated with the use of fluoroquinolones. <i>CMAJ</i>. 2013;185(10):E475-482. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23734036\">[PubMed 23734036]</a></p>\n<p>2. Savage R. Ciprofloxacin, enalapril and acute kidney injury: strengthening of a drug interaction signal. <i>WHO Pharmaceuticals Newsletter</i>. 2018;1:16-21.</p>\n<p>3. Fralick M, Macdonald EM, Gomes T, et al. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. <i>BMJ</i>. 2014;349:g6196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25359996\">[PubMed 25359996]</a></p>\n<p>4. Antoniou T, Hollands S, Macdonald EM, Gomes T, Mamdani MM, Juurlink DN, Canadian Drug Safety and Effectiveness Research Network. Trimethoprim-sulfamethoxazole and risk of sudden death among patients takingspironolactone. <i>CMAJ</i>. 2015;187(4):E138-E143. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25646289\">[PubMed 25646289]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12071":"<p><b>Title</b> CloZAPine / Amisulpride</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Amisulpride may enhance the adverse/toxic effect of CloZAPine. Use of the combination may be associated with an increased risk of movement disorders, significant QT interval prolongation, and other adverse effects. CloZAPine may increase the serum concentration of Amisulpride. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Concurrent use of amisulpride with other antipsychotics, such as clozapine, should be avoided.</p> \n<p><b>Discussion</b> According to the amisulpride summary of product characteristics, concurrent use with other antipsychotics should be avoided.<sup>1,2</sup><br><br>Dose-corrected plasma concentrations of amisulpride were approximately 2-fold higher in patients who received clozapine and amisulpride concomitantly (n=7) than in those who received amisulpride alone (n=13) in one study.<sup>3</sup> Amisulpride concentrations were 1.2-fold higher (not statistically significant) according to a study using data from a therapeutic drug monitoring service in patients who were co-prescribed clozapine with amisulpride (n=16) as compared to those treated with amisulpride alone (n=268).<sup>4</sup> Consistent with these data, the UK labeling for amisulpride states that coadministration of amisulpride and clozapine may lead to an increase in plasma concentrations of amisulpride.<sup>5</sup> The likely mechanism of this pharmacokinetic interaction is unclear, but it has been suggested that amisulpride and the main clozapine metabolites (clozapine-N-oxide and N-desmethylclozapine) may compete for renal transport.<sup>6</sup><br><br>Both amisulpiride and clozapine are associated with a moderate risk for significant prolongation of the QT interval. Consequently, use of the combination could also be associated with an increased risk for clinically meaningful prolongation of the QT interval or proarrhythmic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Solian (amisulpride). Guildford, Surrey, United Kingdom: Aventis Pharma Limited; January 2013.</p>\n<p>2. Summary of product characteristics. Solian (amisulpride). Quetigny, France: Sanofi Winthrop Industrie; November 2012.</p>\n<p>3. Bergemann N, Kopitz J, Kress KR, Frick A. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. <i>Eur Neuropsychopharmacol</i>. 2004;14(3):245-250. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15056484\">[PubMed 15056484]</a></p>\n<p>4. Bowskill SV, Patel MX, Handley SA, Flanagan RJ. Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002-2010. <i>Hum Psychopharmacol</i>. 2012;27(5):507-513. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22996618\">[PubMed 22996618]</a></p>\n<p>5. Solian (amisulpride) [summary of product characteristics]. Guildford, Surrey, United Kingdom: Aventis Pharma Limited; November 2017.</p>\n<p>6. Bergemann N, Kress KR, Frick A, Kopitz J. Amisulpride has no effect on plasma clozapine concentrations. <i>J Clin Psychopharmacol</i>. 2005;25(5):494-497. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16160629\">[PubMed 16160629]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12072":"<p><b>Title</b> Vaccines (Live) / Tildrakizumab-asmn</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tildrakizumab-asmn may enhance the adverse/toxic effect of Vaccines (Live). The risk for contracting an infection from the vaccine may be increased. Tildrakizumab-asmn may diminish the therapeutic effect of Vaccines (Live). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid administration of live vaccines to patients who are being treated with tildrakizumab-asmn.</p>\n<div>\n <p><b>Vaccines (Live) Interacting Members</b> Adenovirus (Types 4, 7) Vaccine, BCG Vaccine (Immunization), Cholera Vaccine, Influenza Virus Vaccine (Live/Attenuated), Japanese Encephalitis Virus Vaccine (Live/Attenuated), Measles, Mumps, and Rubella Virus Vaccine, Measles, Mumps, Rubella, and Varicella Virus Vaccine, Poliovirus Vaccine (Live/Bivalent/Oral), Poliovirus Vaccine (Live/Trivalent/Oral), Rotavirus Vaccine, Smallpox Vaccine Live, Typhoid Vaccine, Varicella Virus Vaccine, Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated)</p>\n</div> \n<p><b>Discussion</b> The prescribing information for tildrakizumab-asmn states that administration of live vaccines should be avoided, and patients should get all necessary vaccinations prior to starting tildrakizumab-asmn whenever possible.<sup>1</sup> There is no specific data regarding this interaction, but tildrakizumab-asmn interferes with normal inflammatory and immune response.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ilumya (tildrakizumab-asmn) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; March 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12073":"<p><b>Title</b> Methotrexate / Nitrous Oxide</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Nitrous Oxide may enhance the adverse/toxic effect of Methotrexate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant nitrous oxide anesthesia in patients receiving methotrexate. Use caution when administering methotrexate after a recent history of nitrous oxide administration.</p> \n<p><b>Discussion</b> Published case reports describe patients experiencing severe neurotoxicity (e.g., weakness, dysarthria, somnolence, severe agitation, and seizure activity) following administration of intrathecal methotrexate under general anesthesia with inhaled nitrous oxide.<sup>1,2</sup> The prescribing information for methotrexate states that the concomitant use of methotrexate and nitrous oxide anesthesia should be avoided due to the potential for increased toxicity such as stomatitis, myelosuppression, and neurotoxicity.<sup>3</sup> Caution is also advised when methotrexate is administered following a recent history of nitrous oxide use.<br><br>The proposed mechanism for this potential interaction is a simultaneous reduction of folate and vitamin B-12 via coadministration of methotrexate and nitrous oxide, resulting in the potential for increased methotrexate toxicity.<sup>1,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Forster VJ, van Delft FW, Baird SF, et al. Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients. <i>Cancer Chemother Pharmacol</i>. 2016;78(5):1093-1096. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27659182\">[PubMed 27659182]</a></p>\n<p>2. Lobel U, Trah J, Escherich G. Severe neurotoxicity following intrathecal methotrexate with nitrous oxide sedation in a child with acute lymphoblastic leukemia. <i>Pediatr Blood Cancer</i>. 2015;62(3):539-541. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25360802\">[PubMed 25360802]</a></p>\n<p>3. Methotrexate injection [prescribing information]. Lake Forest, IL: Hospira, Inc; March 2018.</p>\n<p>4. Ermens AA, Schoester M, Lindemans J, et al. Effect of nitrous oxide and methotrexate on folate coenzyme pools of blast cells from leukemia patients. <i>Leuk Res</i>. 1991;15(2-3):165-171. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2016907\">[PubMed 2016907]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12074":"<p><b>Title</b> CycloSPORINE (Systemic) / Nystatin (Oral)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Nystatin (Oral) may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> A single case report describes a 25-year-old female maintained on cyclosporine (225 mg per day) for lupus panniculitis with stable cyclosporine concentrations (100 to 200 ng/mL) and normal liver function tests experienced a supratherapeutic cyclosporine concentration (586.6 ng/mL), a 4-fold increase in AST, and a 2-fold increase in ALT one day following the addition of nystatin (1 million units orally three times daily).<sup>1</sup>. Discontinuation of nystatin, skipping one dose of cyclosporine, and reducing the cyclosporine dose to 150 mg per day resulted in a decrease in cyclosporine plasma concentration to 121.9 ng/mL and return of liver function tests back to baseline 5 days later. The cyclosporine dose was eventually titrated up to 200 mg per day approximately 2 weeks after nystatin discontinuation.<sup>1</sup><br><br>The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Liu W, Guan X, Yu Z, Chen K, Benet L, Zhai S. A drug-drug interaction between cyclosporine and nystatin [published online March 15, 2018]. <i>Clin Ther</i>. doi: 10.1016/j.clinthera.2018.02.008. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29551534\">[PubMed 29551534]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12075":"<p><b>Title</b> Rilpivirine / Saquinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Saquinavir may enhance the arrhythmogenic effect of Rilpivirine. Saquinavir may increase the serum concentration of Rilpivirine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Coadministration of saquinavir/ritonavir with rilpivirine is contraindicated. Switching from rilpivirine to saquinavir/ritonavir with less than a 2 week washout period is also contraindicated.</p> \n<p><b>Discussion</b> Specific data concerning this combination is not available, but the saquinavir labeling contraindicates concurrent use with rilpivirine due to the risk for possibly dangerous arrhythmias.<sup>1</sup> Rilpivirine does not appear to have a substantial QT prolonging effect at therapeutic concentrations, but at supratherapeutic concentrations, some more significant QT prolongation has been apparent.<sup>2</sup> As saquinavir/ritonavir is a CYP3A4 inhibitor, this combination would be expected to increase rilpivirine concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Invirase (saquinavir) [prescribing information]. South San Francisco, CA: Genetech, Inc.; March 2018.</p>\n<p>2. Edurant (rilpivirine) [prescribing information]. Titusville, NJ: Janssen Products, LP; March 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12076":"<p><b>Title</b> Saquinavir / Erythromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Erythromycin (Systemic) may enhance the arrhythmogenic effect of Saquinavir. Erythromycin (Systemic) may increase the serum concentration of Saquinavir. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Coadministration of saquinavir/ritonavir with erythromycin is contraindicated.</p> \n<p><b>Discussion</b> The saquinavir AUC was approximately 2-fold higher with concurrent administration of erythromcyin in a study of healthy volunteers.<sup>1</sup> The saquinavir labeling contraindicates concurrent use with erythromycin due to the risk for possibly dangerous arrhythmias.<sup>2</sup> Both saquinavir and erythromycin have been associated with some degree of QT interval prolongation, and the possibility of increased drug concentrations could further increase any risk.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Grub S, Bryson H, Goggin T, Ludin E, Jorga K. The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. <i>Eur J Clin Pharmacol</i>. 2001;57(2):115-121. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11417442\">[PubMed 11417442]</a></p>\n<p>2. Invirase (saquinavir) [prescribing information]. South San Francisco, CA: Genetech, Inc.; March 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","12077":"<p><b>Title</b> Pentamidine (Systemic) / Saquinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Saquinavir may enhance the arrhythmogenic effect of Pentamidine (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Coadministration of saquinavir/ritonavir with pentamidine is contraindicated.</p> \n<p><b>Discussion</b> The saquinavir labeling contraindicates concurrent use with pentamidine due to the risk for possibly dangerous arrhythmias.<sup>1</sup> Both saquinavir and pentamidine have been associated with some degree of QT interval prolongation. Whether any risk extends to orally inhaled pentamidine is unclear as there is less data indicative of a meaningful QT prolonging effect of inhaled pentamidine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Invirase (saquinavir) [prescribing information]. South San Francisco, CA: Genetech, Inc.; March 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}